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ABSTRACT 
Psychornotor performance, drowsiness and anxiety were ~easured 
in 70 anxious outpatients in a randomized double-blind, placebo~ 
controlled trial comparing the 1,5 benzodiazepine clobazam (10 
mg ~~t!Jg, times a day) to lorazepam (1 mg ~}~\times a day). 
Carefully selected tests were adminf~tered pre-tre~tment and 
at 2 and 9 days after treatment. Compliance was checked by 
blood assays. 
There was a significant improvement in anxiety in ·the cloba-
zam, lorazepam and placebo gioups at 2 days and a furth~r 
improvement at 9 days but only in the clobazam and lorazeparn 
groups. Th~ lorazepam patients had a significantly higher 
overall drowsiness ratin~ than the clobazam and placebo 
groups. Both the clobazam and place~o groups showed an 
improvement over time in choice reaction time, the Di~it 
Symbol Substitution Test, Purdue Pegboard tests and the Inglis 
paired-associate learning test. There was no change·in 
critical flicker fusion threshold. The lorazepam-treated 
patients demonstrated exactly the same pattern on psychomotor 
performance tests except that tnere was an impairment in two 
of the Purdue pegboard tests on day 2. On the basis of 
previous volunteer studies with lorazepam, a far more general 
and consistent impairment of psychomotor performance was ex-
pected with that drug. This indicates that the finding 
derived from normal volunteer~ cannot necessarily be extra-
polated to anxious patients. The possible reasons for the· 
I . 
xi·· 
different iesponses in volunteers and patients are discussed. 
The practical implications of the vatious findings and th~ 
recommendations for future research are also-considered.· 
' 
" 
\ 
..... ' 
· .. 
. ' . 
. ·, ,· 
1 
I. THE BENZODIAZEPINES 
1.1 EXTENT OF PRESCRIPTION OF THE BENZODIAZEPINES 
The benzodiazepines are among the most widely prescribed classes 
of drugs. From 1964 - 1972, the number of prescriptions for 
anxiolytic drugs doubled in the United States. Virtually 
all of this increase was attributable to an increase in the 
use ~f benzodiazepines, specifically diazepam (Blackwell, 
1973). Hollister (1981) writes that one might have con-
cluded, were one to extrapolate from the curve, that by 1984 
everyone in the United States would be on diazepam. However, 
1972 was the peak of use and in the subsequent 7 years, 
prescriptions for these drugs hav~ declined_ by about 22 
percent. 
Information about the use of benzodiazepines come~ from' 
prescription audits, national and local household surveys, 
and surveys conducted in family practice. In the United 
States during 1973 the total number of prescriptions filled 
in drug stores for all drugs was 1 500 million. Of these, 
223,2 million were for psychotherapeutics and 80 million 
of them were benzodiazepines (Rickels, 1981). Survey data 
taken during 1972 indicateQ that 15 percent of re~pondents 
had used a benzodiazepine over the previous year in the 
United States. In Western European countries use ranges 
from a low of 10 percent in Spain to a high of 17 percent 
\ . 
in Belgium, with. the United Kingdom reporting an incidence 
of 14 percent. In the United States one third of the 
benzodiazepine users were high users, the~ had taken their 
' ' ' 
medication regularly for two months or more~ one third ~ere 
. .. '• 
intermediate users and the remaining third Wer~ low user~ 
(Rickels, 1981). There is a prevalence of use in females 
over males, the approximate proportion is two.female users 
for every m~le user (Bellantuono et al., 19aO). 
1.2 TYPES OF BENZODIAZEPINES 
The phenothiazine tranquilisers were developed in the ~arly 
1950s. They made a t:remendous ·Contribution to the drug 
treatment of severe psychological problems, specifically. 
schizophrenia. In addition, antidepressant drug~ had been 
developed to treat depression. However, by 1960 the ·drug · 
treatment of anxiety symptoms was not promising •. · The barbi~ 
turates had a general nonspecific sedative effect and 
meprobromate, although init~ally thought to be an improvement, 
was later shown to add little if any therapeutic benefit 
to that available from th~ barbiturates (Greenblatt and 
Shader, 1974). Thus the development of the benzodiazepines 
which began in the early 1960s has made a major contribution 
in the drug treatment of anxiety. 
The first benzodiazepine.to be developed was chlordiazepoxide 
(trade name - librium). This was followed by the development 
of diazepam (most commonly use~ trade name - valium). Other 
important well known benzodiazepines include nitrazepam 
(trqde name - mogodon) and lorazeoam (trade name - ativan). 
All these benzodiazepines have the nitrogen atoms situated 
at positons 1 and 4 in the heterocyclic ririg and are called 
1,4 benzodiazepines. A diagram of the chemical structure 
of diazepam, the most commonly used 1,4 benzodiazepine, 
can be seen in Appendix l; In the early 1970s a benzodiaze-
pine with the nitrogen atoms in positions 1 and 5 in the 
heterocyclic ring was developed. This 1,5 benzodiazepine 
is called clobazam (trade name.- urbanol) and a diagram of 
its chemical structure can be seen in Appendix 1. 
1.3 THE CLINICAL INDICATIONS OF THE BENZODIAZEPINES 
The benzodiazepines have a well .established set of clinical 
indications that follow closely their. pharmacological 
effects. These indi~ations are: anxiolytic, hypnotic, 
muscle relaxant, anticonvulsqnt, and ~naesthetic (Hollister, 
1981). 
The efficacy of the benzodiazepines in alleviating anxiety 
has been established in double-blind, plac~bo ~ontrolled 
. . 
studies. Bellantuono et al. (1980) in their review of 
these studies, report that ou~ pf a total of B5 studies compar-
ing a benzodiazepine with a placebo, 44 results showed the 
drug .to be much better, 26 showed the drug to be slightly 
better, 14 showed no difference and one study showed the 
drug to be worse than the placebo. 
.. 
The benzodiazepines are mainly prescribed as antianxiety 
, agents and to alleviate sleep disturbances. The muscle 
relaxant properties of benzod~azepines (mainly diazepam) 
are an indication for their use in some neurological distur-
bances for symptomatic relief of muscle ~pasms and spasticity. 
The muscle relaxant effect when combined with the sedative 
effect make the benzodiazepines useful for anaesthetic and 
pre-anaesthetic proc~dures (Bellantuono et al., 1980). Some 
benzodiazepines also have a role in anticonvulsive treatment . 
1.4 THE EFFECTS OF THE BENZODIAZEPINES 
The benzodiazepines have a number of effects: anti-anxiety, 
anticonvulsant, muscle relaxant and sedation. Sedation 
is viewed as having two components: (a) the patient's 
subjective reports of drowsiness, sluggishness and apathy, 
and (b) objective indications of impaired .. performance on 
various tasks. Aspects of this latter c6mponent will be 
considered in detail in later parts of the introduction •. 
The sedative effect can be useful if the drug is prescribed 
as a night-time hypnotic and here drowsiness and sleep ar~ 
the desired effects. However, if the benzodiazepines are 
given during the daytime as antianxiety agents they .are 
meant to reduce anxiety without producing generalised 
sedation (Greenblatt .and Shader, 1974). Any behavioural 
impairment is undesirable and particularly so for these~· 
persons who are involved in working with heavy machinery .. 
or who drive a motor vehicle (Clayton, 1976 and Kibrick 
~nd Smart, 1970). 
Silverstone (1974) GOnsiders whether accidents are2more 
common among patients taking psychotropic drugs than among 
similar patients not taking psychotropic drugs. 
ing this question he writes (p.452): 
In consider-
1.5 ANXIETY 
"The epidemiological information to date is in-
conclusive. On the one hand are studies which 
suggest that centrally acting drugs other than 
alcohol are a relatively unimportant factor 
in road traffic accidents. On the other hand 
there are studies which implicate centrally 
acting drugs much more. An example of the 
first is that reported by Walker (1971) in 
which blood sample$ were taken from those dying 
within 15 min of a single vehicle road traffic 
accident. The proportion of those who were 
found to have barbiturates (7 percent) or,' 
tranquillizers (1 percent) in their blood was 
not greater than that expected in the general 
population of California where the study took 
place. In sharp contrast to that finding 
i$ the earlier report by Murray (1960) describing 
a ten-fold increase in the expected road traffic 
accident rate among 68 drivers taking chloradiaze-
poxide over a 90 day period. Similarly a 
Japanese survey of taxi drivers who were taking 
tranquillizers revealed an increased accident 
rate among them as compared to non drug takers 
(Milner, 1972)." 
Sine~ the benzodiazepines are mainly prescribed to alleviate' 
anxiety, the following will be briefly considered; a 
definition of anxiety; methods of alleviation of anxiety 
and the advantages and disadvantages of the anxiolytics for 
alleviating anxiety. 
5 
1.5.l A Definition of Anxiety 
Anxiety is not an easy concept to define and there ,are 
various approaches to viewing the concept depending on one's 
theoretical orientation. A very useful approach is to 
list the major characteristics of anxiety. 
very adequately by Lewis (p.14, 1980): 
This is done 
11 1. It is an emotional state, with the subjectively 
experienced quality of fear or a closely 
related emotion. 
2. The emotion is unpleasant. 
3. It is directed towards the future. 
4. There is either no recognisable threat, or 
the threat is, by reasonable standards, 
quite~out of proportion to the emotion it 
seemingly evokes. 
5. There are subjective bodily discomforts during 
the period of the anxiety. These include the 
sense of constriction in the chest, tightness 
in the throat, difficulty in breathing and 
weakness in the legs. 
6. There are manifest bodily disturbances. These 
include dryness of mouth, sweating, palpitations, 
abdominal pain and giddiness. 11 
Lewis (p.15) also lists those attributes which at some time 
have been included in the criteria of anxiety, but which 
he feels should be dispensed with as criteria of recognition 
of anxiety. Anxiety may be: 
11 1. normal (student taking an examination) or 
pathological. 
2. mild or severe. 
3. mainly detrimental to thought and'action, or 
in some respects advantageous. 
6 
4. episodic or persistent {chronic) 
5. due to physical disease' {e.g. delirium 
tremens) or psychogenic. 
6. accompanying other features of mental disorder 
or alone. 
7. may for the duration of the attack affect 
perception and memory .or may leave them intact. 11 
1.5.2 Methods of Alleviation of Anxiety 
Any approach that hopes to deal successfully with psycho-
logical problems will need to take account of the fact that· 
those problems, e.g. anxiety, do not occur.in isolation 
from the persons environment. Thus an adequate assessment 
of the person-environment system is essential. Different 
approaches tend ·to concentrate on different aspects of this 
system. Thus a broader appro,ch such as family therapy 
would focus on the person's familX environment whereas more 
individual approaches would ~oncentrate more dir~ctly on 
the person. Psychotherapeutic approaches to anxiety 
problems include psychotherapies within the psychoanalytic, 
behavioural and humanistic-existential orientations. ·Drug 
treatment of anxiety problems can be viewed as a biologically 
based approach focusing on the indi~idual. 
1.5.3 Disadvantages and Advantages of Anxioly~ics 
The drug treatment of anxiety has various advantages. It 
has been shown in carefully controlled studies to be effective 
7 
in reducing anxiety. Anxiolytics are not time~consuming 
to administer and they do not reqOire:the use of techniques 
outside the experience of most doctors (Lader and M~rks, 
1971). Therefore in situatlons when the supply of trained 
psychotherapists and social workers is inadequate to meet 
the needs of the population drug treatment offers a useful 
alternative. However, unlike psychotherapy which generally 
increases the.person's ability to deal with anxiety. (e.g. 
relaxation training), drug treatment only alleviates the 
person's discomfort. Thus ideally psychotherapeutic 
approaches are preferred relative to drug tre~tment. Un-
fortunately psychotherapeutic approaches are frequently 
8 
. ( . 
not available, are often financially unfeasible, or may in 
some instances represent in the ~atient's opinion an unaccept-
able alternative (Rickels, 1981). Therefore, as previously 
discussed, the benzodiazepines are widely prescribed and 
constitute the most commonly used approach to alleviate 
anxiety. 
1.6 EVALUATION OF DRUGS - CLINICAL TRIALS 
All prescribed drugs are evaluated according to their efficacy 
and safety (Taber, 1969). This is a complex process 
beginning with animal studies and then assessing the effects 
of these drugs in humans. The final phase and the·crucial 
test of effectiveness of a drug is the controlled clinical 
trial. Uncontrolled trials are also carried out in the 
early stages of research. These involve administering 
the phafmacologic agent to subjects and observi·ng the 
target ~ffects. The most important limitatio~ of this 
approach is the failure~o assess the contribution of 
placebo effects in psychotropic drug research. It 'is well 
known that target symptoms may appear or disappear either 
spontaneously in response to the aura of investigation, in 
response to the e~p~ctation of change, or because of 
investigator bias. For these reasons, the relevant pharma-
cologic agent should always be evaluated relative to a 
placebo which is an inert chemical s~bstanc~ administered 
in a way to make it indistinguishable from the pharmacologic 
agent. Uncontrolled trials can suggest whether further 
controlled study is indicated (Greenblatt and Shade~, 1974). 
The controlled clinical trial includes the use of a placebo. 
Neither the subjects nor the investigator. is aware whether 
the substance taken is active or the placebo. This is 
known as a double-blind trial and is designed to deal with 
the placebo effect and investigator bias. However, 'the 
controlled clinical trial has not solved all the methodo-
logical problems of psychotropic drug research and numerous 
valid criticisms have been raised (Greenblatt and Shader, 
1974). 
Five of these points will be considered. A summary of the 
points of debate is presented by Greenblatt and Shader in 
the form of claims and counter-claims. 
9 
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The first involves the claim that administering a placebo 
to a symptomatic patient is unethical. 
the following counter-claims: 
This is met by 
"(a) The treatment of millions of patient~ 
with a drug whose efficacy is not 
established is hardly ethical. 
(b) Depriving a neurotic patient of 
active medicaiton during a drug 
study is not akin to withholding 
penicillin from a patient with 
pneumoccal penumonia. 
(c) An active medication may be used 
instead of placebo as a reference 
·substance" (Greenblatt and Shader, 
p.55, 1974). 
... 
The ~econd is the claim that controlled trials are performed 
in a rigid, sterile, investigative setting and results there-
fore are not applicable to t~e setting of the usual doctor-
patient relationship. This is countered by the as~ertton . 
that valid psychopharmacological research may be performed 
within ongoing private practices and clinics, with no· 
disruption of the therapeutic relationship. 
The third claim is that the onset of action of the drug may not·· 
occur within the duration of the trial. ~he counter-clai~ 
to this is that the effects of anti-anxiety agents, when 
they occur, are almost always seen within seven days of 
therapy. Most drug trials last at least this long. 
Fourthly, it is claimed that overall results of studies 
on large numbers of patients do not predict whether the 
drug will be of benefit to an individual patient.. However, 
nothing can unequivocally predict an individual's .response· 
to a drug. Physicians deal with probabilities, most 
reliably provided from experience with large numbers of 
patients. 
The fifth important claim is that "double-blind" is seldom 
realistically valid. Both patient and investigator can 
distinguish between .active and inactive medications on the· 
basis of pharmacologic effects and side effects. There 
is no definitive counterclaim to this potential of non-
blindness in the double design. This is a weakness 
which must be recognized and with which. investigations 
must live. It should be noted that between.30% to 60% 
of anxious patients respond to placebo improving in anxiety 
and showing some side-effects similar to those found when 
they are given benzodiazepines. Thus the potential for 
non-blindness is less in clinical trials involving be~zo­
diazepines than in clinical trials in general. 
Another set of problems ·which plagu~s psychotropic drug 
research involves the "nonspecific" factors in drug. 
ther~y: characteristici of patient, physician, treatment 
setting, and disease which influence the response to drug 
and placebo, and hence the potential drug-placebo difference. 
The studies assessing non-specific factors in anti-anxiety 
drug therapy are summarized by Greenblatt and Shader. For 
example, Rickels et al. (1971) found that males improved 
more on drug than females, but the same on placebo. The 
influence of the various factors differs from study to study 
...... 
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and in some cases different investigators have .. ~::a·und.the 
same nonspecific factor to influence results in different 
di re ct ions • These nonspecific factors have.to be. 
considered when interpreting results of studies •. ' A 
. . . 
positive result could be due eith~r t6 si~~ng drug effects 
which overwhelm the nonspecific factors or to a fort~itous 
combination of non-drug factors which exaggerate th~ drug-. 
placebo differences. A negative result could be due.to 
an ineffective drug or to the influence of non-specific 
factors. Far more research has tb be don~ on the 
influence of nonspecific factors in the drug treatment of 
anxiety. One possible result of further.research is that 
generalizations about drug efficacy will be m~de with 
increasing reservation and limitation (that is with more 
specificity and sophistic~tion). 
12 
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2. PSYCHOMOTOR FUNCTION 
2.1 DEFINITION 
Hindmarch (p.190, 1980) has defined psychomotor performance 
as "the coordination of sensory and motor systems involved 
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i n the exec LI t i on of s k i 1 1 e d tasks res u 1 t i n g in reg u 1 a ted per for -
mance to meet the demands of the task, and the needs of the 
individual". This coordination of the motor system with 
sensory inputs to achieve synchronised, integrated behaviour 
and performance of skilled tasks is one of the most important 
functions of the cerebral cortex and associated sub~cortical 
centres. The range of behaviour is extensive in that the 
level of skill required for its performance ranges from 
simple coordination as in picking up a small object to the 
complex sensori-motor integration involved in ca~ driving. 
Hindmarch (p.190, 1980) represents the various aspects 
involved in psychomotor performance schematically: this is 
reproduced overleaf as Figure 1. 
Hindmarch then goes on to the various tests of psychomotor 
function which have been shown to be sensitive to a wide 
range of psychoactive drugs. These are summarized in 
Figure 2 which is reproduced from Hindmarch (p.201, 1980). 
This figure also clearly indicates the various components 
of performance, i.e. sensory, central nervous system, motor 
and overall coordination activity. This is discussed 
Environmental . 
stimulation 
Sensory 
Primary 
coding 
Central nervous system 1--~~~- r~~~--t 
Central 
recoding 
and 
analysis 
···~:. 
Integration Central 
organisation 
of 
output 
Motor 
Overt 
behaviour.· 
Coordinated . 
behavioural 
responses 
FIGURE 1: Psychomotor performance results from the co-
ordination of sensory and mote~ systems through 
the integrative and organisational procP.sses of 
the brain and central nervous system. The·pro-
cessing of sensory information is influenced by 
personality, memory and individual motivation, 
while the overall function of the integrative 
mechanism is governed by the state of arousal 
of the central nervous system. Complex feed-
back and adaptive systems complete the process 
by which environmental stimuli produce appro-
priate, co-ordinated behavioural responses. 
SENSORY 
Stimulus 
PSYCHOMOTOR PERFORMANCE 
Card sorting : Choice reaction time 
CENTRAL NERVOUS SYSTEM MOTOR" 
' 
detection Perception Recognition Processing Integration Memory Learning Ballistic ' Gross Fine Coordination 
Auditory Letter Digit Mental Critical Digit Verbal Finger Stabilometer Hand · Peg 
vigilance cancellation symbol arithmetic flicker fusion span learning tapp· s d" mg tea mess board 
SENSORl-MOTOR PERFORMANCE 
SIMPLE REACTION TIME : PURSUIT 
ROTOR 
FIGURE 2: A summary of tests of psychomotor fun6tion which 
have been shown to be sensitive to a wide range 
of psychoactive drugs. 
t 
further on page 21 of this introduction. 
The relationship between arousal and performance and the 
relationship between anxiety and performance which are both 
important in understanding drug effects on p~ycho~otor per· 
formance will now be considered. 
2.2 AROUSAL AND PERFORMANCE 
Our level of conscious awareness fluctuates over time. 
These fluctuations in conscious awareness are not discrete 
steps but represent a continuously variable state from sleep 
at one end to extreme panic at the other end. The major 
stimulant and sedative drugs can be thought of as an arti-
ficial means of altering the level of arousal of. an individual. 
Stimulant drugs shift the individual towards a ~tate of higher 
arousal while sedatives will shift him in the opposite 
direction (Clayton, 1970). 
There is ~n inverted U relationship'between degree of arousal 
and psychomotor performance. Up to a certain critical point 
increased arousal leads to improved performance, however, 
beyond this critical point further arousal leads to a 
deterioration of performance. This relationship is relevant 
when one wishes to inter~ret the. effects of drugs, that alter 
the level of arousal, on performance. · 
Besides this general effect, on the level of arousal and the 
consequent effect on psychomotor performance, sedative and 
15 
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stimulant drags also have two more specific influences on 
alertness which alter performance. Performance ot ~epetitive 
tasks, such as observing a radar screen does not proceed 
uniformly. Instead, it is punctuated by a series of brief 
involuntary rest p0uses lasting a second or two, w~en the 
subject takes time off from the task in order to recuperate. 
These rest pauses are noticed subjectively as lapses ·of 
attention and are often followed by a brief period of feeling 
more than usually wide awake. Objectively they appear in 
performance as blocks or gaps when no response is made. 
Clayton (1970) writes that the exact physiological basis of 
these pauses is unknown, but their onset is probably due to 
the gradual accumulation, in the nervous system, of an 
inhibitory process which the pause allows to be dissipated. 
These involuntary rest pauses are more likely to occur in 
states of low arousal and one way in which sedative drug~ 
impair performance on vigilance tasks is by increasing the 
likelihood of rest pauses occurring (Clayton, 1970}. 
Stimulant drugs, on the other hand, delay the onset of rest 
pauses and increase the chances that the subject is paying 
attention when a signal occurs during a vigilance task. This 
changing of the frequency with which the brain takes a rest 
is one way in which it reacts to shifts in its arousal level 
whether this is induced by drugs or the external environment. 
Normally then rest pauses only become a nuisance under 
rather special conditions of extreme monotony and even then 
only after sufficient.time has elapsed for a rest pause to 
become necessary. 
. ... ·' :- ...... : _.::: ..... 
There is, however, another more immediat~ way. in which our 
attention to the environment is altered in ~ifferent states 
of physiological arousal. As arousal level rises the number 
and range of stimuli to which we pay attention {iminishes. We 
become less distracted by stimuli that are not our immediat~ 
concern. 
These several ways in which an individual's responsiveness 
to the environment can be altered by drugs normally occur 
together. Thus, the individual whose arousal l~vel .is 
shifted upward by a stimulant drug will becbme generally 
more alert, will show narrowing of attention, and will be 
less affected by monotony. The per~on's-psychomotor 
performance will therefore be improved. Alternatively, a 
person taking a sedative drug will become generally less 
alert, will be more distracted by irrel~vant stimuli and 
will be more affected by monotony and ~onsequently their 
psychomotor performance will deteriorate. 
2.3 ANXIETY AND PERFORMANCE 
Yerkes and Dodson (1908) described the r~la~i~~~hip between 
drive strength and performance. There is an inverted U-
shaped curve relating drive to performance. The relation-
ship implies that for each task there is an optimum· drive 
level, both above and below which performance falls off. 
The optimum drive level varies with differerit tasks .. For 
easy tasks this optimum drive level is high, whereas for 
difficult tasks it is low. These relationships ate 
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perform taks which are very easy. 
The inverted LI-relationship between drive (e.g. anxiety) 
and performance can be us:e-_d to explain why an anxious person's 
performance can improve if they are taking anxiolyt~c medica-
tion. If their initial anxiety level is high thus situating 
them on- the downward part of the inverted LI-curve a decrease 
in anxiety brought about by medication would result in them 
being situated more towards the top of the U-curve,that is to 
sa~ their performance will improve. Depending on the person's 
initial anxiety level anxiolytic medication may also result in 
diminished performance or no alteration in_ performance level. 
The same possibilities of performance either not chan~ing or 
improving or deteriorating depending on the person's initial 
state also apply to arousal level which as previously indicated 
also has a LI-shaped relationship with performance. 
2.4 THE SELECTION OF ASSESSMENTS AND POPULATION GROUPS IN 
PSYCHOMOTOR PERFORMANCE STUDIES 
Wittenborn (1980) discusses the need to develop a standard 
battery of tests to assess the behavioural cons~quences of 
psychotropic substances. He writes.(p.171); "No standard 
battery would be sufficient to show all of the therapeutfc 
potential or all of the untoward reactions consequent to many 
psychotropic substances. Nevertheless, knowledge of ~ 
psychotropic substances in terms of a limited spectrum of 
responses could serve as standard benchmarks and would make 
all drugs subject to at least minimal comparison." 
.· ·.·. 
·, :· 
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This knowledge would be useful in identifying at an early 
stage those drugs that caused considerable psychomotor 
impairment. In addition the knowledge :could also.help to 
facilitate the identification of psychotropic substances of 
therapeutic promise. The probable nature of the thera-
.. 
peutic consequences of a new drug might be suggest~d by 
considering the therapeutic effect of tho~e familiar drugs 
which involve a pattern of behavioural responses_ similar to 
the new substance. Besides these two practical advantages 
the knowledge gained from such research will be of value in 
its own right, and even in the absence of immediate practical 
application it can be the basis for the generation of further 
knowledge which may indeed be practical. 
The ~stablishment of a standard assessement battery to assess 
the effects of psychotropic drugs on psychomotor performance 
involves the consideration of two questions. .· First, what 
' ' 
assessments would best serve the purposes of such a program? 
Second, what population·should be chosen to provide .the 
standard referent responses? 
2.4.l The Selection of Assessments 
A broad spectrum of psychomotor tests .has been used in 
studying the behavioural effects of the benzodiazepines. 
Wittenborn asserts that researches have not been systematic 
in their selection of psychomotor tests. · One reason for.: 
' ' ' 
this is that there is no theory to guide the researcher iri 
the selection of the behaviours and tests most appropriate 
I 
21 
for showing psychotropic drug effects. Wittenborn therefore 
proposes that the best alter~ative is to use a pragmatic 
approach and to choose measures that are generally sensitive 
to detecting behavioural effects. A ~ensitive m~a~ure is 
one which has been shown to be able·to detect significant 
differences in the behavioural effects of a 1,4 benzodiazepine 
relative to a placebo in a large proportion of the studies 
using that measure. Thus ciritical flicker fusion thresh-
hold is a very sensitive measure; in five studies there 
were five discriminations between drug and placebo. Other 
t 
measures which Witenborn in his review found to be very 
~ 
sensitive in studies during the first day of medication given 
to non-patient volunteers are measures of learning and memory, 
time estimation, the digit symbol substit~tion test, 
cancellation and card sorting~ All signifi~ant effects 
showed the 1,4-benzodiazepine to have a detracting or dis-
ruptive behavioural consequence. The~e effects are dis-
cussed in more detail in a later section of the introduction. 
Another important criterion which is not discussed by 
Wittenborn but emphasized by Kleinknecht and Donaldson (1975) 
and Hindmarch (1980) is to select tests so that the total 
battery would assess the whole range of the important 
components of psychomotor performance.· The components and 
the various tests are clearly shown in the figure reproduced 
from Hindmarch (p.201,. 1980). This is figure .2 on page 14 
' . 
of this introduction. The major components are: 
(a) Sensory function and sensory processing ability~ The 
majority of sensory activity is made up of three levels 
. { 
of information processing, i.e. detection~ perception 
and recognition of a stimulus. A sensitive test of 
stimulus detection is the auditory vigilance t~s~. A 
sensitive test of the perception stage is the letter 
cancellation assessment. A sensitive test of the 
recognition stage is the digit symbol substitution. 
test. 
{b) Central nervous system function and central processing 
ability. The two major subcomponents in the area of 
. . 
central nervous system function are integration and 
proces~ing. A sensitive measure of central riervous 
system int e gr at ion (1 eve 1 of a r o us a 1 } i s · the c r it i ca 1 
flicker fusion threshhold. Sensitive measures of 
central proce~sing ability are menta·1 arithmetic and 
tests of memory (digit span test) and learning (verbal 
learning) tasks. 
(c) Motor function and behavioural coordination. This 
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component can be further classified into four components, 
ballistic activity, gross body balance, fine motor 
control and motor manipulative activity (coordination). 
The four corresponding sensitive psychomotor tests for 
each of these.subcomponent~ are finger tapping (ballistic 
activity), Stabilometer performance (gross body balance) 
the Hand Steadiness Test (fine motor contra~) and the 
PegBoard Test (coordination). 
It i s a 1 so i m port an t to i n c 1 u de _ at 1 e a st . on.e <.1: e st. of ov e r a p 
·' 
psychomotor (sensori-motor) performance which involves the 
coordination of the sensory and motor system by the central 
nervous system. Sensitive tests in this area are Simple 
and Choice reaction time, The Pursuit Rotor test·and card 
sorting. 
2.4.2 The Selection of Population Group 
Wittenborn is interested in ascertaining the behavioural 
effects of the benzodiazepines as distinct from .their 
therapeutic effects. Studies on the behavioural effects 
of benzodiazepines in a patient population are not suitable 
for ascertaining the behavioural effects per se because the 
patient's therapeutic ~esponse will affect their performance. 
Since people adapt during the continued administration of. 
psychotropic substances the person's initial response to the 
drug is the best indication of. the behavioural effect per se. 
For these reasons Wittenborn states that the best waf of 
determining behavioural effects per se is to study the 
initial effects (during the first day of medication) on non-
patient subjects. 
·. } 
So if one is interested in ~btaining a clear picture of .the 
behavioural effects of benzodiazepine the approach-advocated 
by Wittenborn is certainly appropriate. However, benzodia-
zepines are prescribed to anxious persons and one is primarily 
interested in the behavioural effects of continued benzodiaze-
pine therapy on these anxious persons. 
. ,. ~ 
If it can be shown that equivalent results are found in 
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volunteer and anxious patient groups then. volunteer studies 
could serve as clear basis for predicting with a large 
degree of confidence what will happen in anxious pa~ients. 
However, until this has been unequivocally shown, and this· 
is certainly not the case at the moment, volunteer studies 
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can at best only suggest what will happen lri anxious ~atients. 
There is therefore a definite need for studies that assess 
the psychomotor performance changes in patients during benzo-
d iazepine .therapy. 
Most research assessing the psychomotor effects of the benzo-
diazepines has been carried out on non-an~ious volunteer~ 
primarily males. (Kleinknecht and Donaldson, 1975, iri their 
reviaw report that 79% of the subjects in the studies they· 
reviewed.were male whereas only 21 percent were female. 
They write that this proportion is not likely to be represen-
tative 6f the clinical uses of diazepam). In fact most 
benzodiazepines are prescribed to anxious persons mainly 
fe~ales (the appropriate proportion is two female usersfor 
every male user (Bellantuono et al, 1980)). (See page 1 ). 
Thus this research can be criticized for failing to carry 
out relevant ~tudies on the actual group of persons (anxious 
mainly females not non-anxious volunteers mainly males) who 
receive benzodiazepine therapy. 
There are a number of factors that have ~ontri~uted to this 
situation. Research on volunteers is far easier to carry 
out from both a practical and ethical point of view than 
research on patients. Another factor seems to be the 
; ,',. 
. . ' '· 25 
.... 
.-·· t 
unthought out acceptance of the idea that results: .foun-d .. in' 
volunteers can be used to predict with confidence what:. 
' 
will happen in patients. The evidence confirmi~g or. 
disproving this idea is in fact only now being ~athered. 
. ' 
Another criticism of research assessing the'psycho~ot~r 
eff~cts of the benzodiazepines i~ the almost total rack of 
- . 
research reports that actually state their rationale .. of test· 
selection. The criteria of test selection discussed 
. .. ;. 
previously in this introduction were ascertained by reading 
various reviews of psychomotor performanc€ studies.· This 
had been do1rte;, prior to reading Hindmarch 's 1980 review which 
carefully discussed similar crite~ia to the ones I had 
decided.on. Most research papers simply state which 
psychom~tor performance measures are being used without 
discussing why these measures are being used. 
Bifore this section of the introductiori is concluded it will 
be worthwhile to consider another issue relatfng to volunte~r 
studies. Research in general investigates the ~ffect of 
independent variables on dependent variables ori a sampl~. · 
. . 
The results found in this sample are. then viewed as being 
representative of the population from which the sample came. 
There is some evidence that volunteers have different 
characteristics from those who do not volunteer for 
behavioural research (Rosenthal and Rosnow, 1969, and Ayd, 
1972). 
RQsenthal and Rosnow write: 
.. . 
"On the basis of studied conducted both in the 
laboratory and in the field, it seemed reason-
able to postulate with some confidence that 
the following characteristics would be found 
more often among people who volunteer than 
. among those who do not volunteer for behavi~ural 
research: 
1. Higher educational level, 
2. Higher occupational status~ 
3. Higher need for approval, 
4. Higher intelligence, 
5. Lower authoritarianism. ~ · 
Two additional and somewhat more complicated 
relationships may also be postulated: · 
(a) In survey-type research volunt~ers tend 
to be better adjusted than nonvolunteers, but in 
medical research volunteers tend to be more 
maladjusted than nonvolunteers. . 
(b) For standard tasks women tend to volunteer 
more than men, but for unusual tasks women tend 
to volunteer less than men. 11 (p.111) 
They write further: 
"To the extent that true volunteers differ from 
nonvolunteers, the employment of volunteer samples 
can led to seriously biased estimates -0f various 
population parameters." (p.112). 
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These ~haracteristics -Of volunteer~subjects shou.ld certainly be 
taken into account·when research with volunteers is carried out. 
One specific factor which is highly relevant to studies 
attempting to assess the effects of benzodiazepines is th~ 
extent of anxiety of the volunteer· subjects~ Ayd (1972) 
found that the psychopathology detected in medical research 
volunteers is usually mild. He asserts that.the proper 
appraisal of the extent of psychopathology can be of value 
in defining the limit~ and specific effects of a dr~g. 
Another approach is to screen out those volunteers that 
deviate from the norm on a relevant characteristic, for 
example, anxiety level. 
2.5 APPROACHES TO ASSESSING PSYCHOMOTOR PERFORMANCE 
Thefe are a number of approaches to assessing psychomotor 
impai~ment (Biehl, 1979). The most important approaches 
are: (a) Laboratory te~ts which assess imp6rtant aspects· 
of performance e.g. reaction time, co-ordination, concentra-
tion, etc. (b) Laboratory studies where p~ychological 
tests are used as indicators of car driving performance. 
(c) · Laboratory studies with simalation where a car driving 
situation is reproduced as realistically as possibla .. 
(d) Field. studies of car driving performance.in.te~t areas 
or in real traffic conditions. 
All the~e approaches~are important to gain a clear picture 
of the psychomotor changes brought about by psychoactiv~ 
drugs (for example the benzodiazepines) .. This study falls 
·into the first category. The first approach is ~asier· 
to employ from a practical standpoint. It yields.general 
knowledge of how psychomotor performance is affected. The 
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other approaches yield more specific practical information ~bout 
car driving performance. 
An important issue relating to the validity of the first 
approach is the extent that findings in th~ labor~tory 
relate to car driving performance. H~kkinen (1976). 
has conducted interesting research into this issue. 
He looked at bus and tram driver accidents· and. ascertained · 
the number of accidents that occurred over a~ specified time 
period. He found thit there was a. iignificant correlation 
between the accident coefficient (the number 6f=accidents 
per year of exposure) of the first B~year~petiod of time 
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and the second period of time which was an average of· 9 years. 
This showed that the accident behaviour (accident proneness) 
of professional city bus and tram drivers was very constant. 
In addition, Hakkinen found that results·~n certain laboratory 
tests of psychomotor performance correlated significantly 
with the accident coefficient. These tests involved 
eye-hand coordination tasks and the more accident prone, 
drivers did worse than the safe drivers on these test~. 
Hakkinen found that the correlations of the' psychomotor 
. ' 
test variables with the accident criterion in different 
exposure periods were bf the same order of magnitude. 
Correlations in the second period were approximately equal 
to those in the first period of time. Multiple regression 
analysis showed that the psychomotor tests could explain 
50 to 65% of the total variance in accident proneness. In 
fact, if the results on the psychomotor tests. were used to 
exclude those drivers who did. badly on the tests when.assessed· 
after the first period of time then the number of accidents 
in the second period would have been greatly reduced. 
' ., 
" . 
.·'. ,. 
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Hakkinen'~ study reve~ls that the use of generalised -
ass es sments of p syc homo tor perf orma nee i Ii t_he I a boratory_ 
does have more specific relevance to the practical·,situa..: .· 
• 
tion of car driving .. · 
·'. 
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3. THE EFFECTS OF THE BENZODIAZEPINES.ON 
PSYCHOMOTOR PERFORMANCE 
3.1 THE EFFECTS OF THE 1,4 BENZODIAZEPINES ON THE PSYCHOMOTOR 
PERFORMANCE OF VOLUNTEERS 
A number of important review articles will be considered to 
ascertain the general trends of how the 1,4 benzodiazepines 
affect psychomotor performance in volunteers as assessed on 
laboratory tests. 
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McNair (1973) reviewed research studies which were concerned 
with the behavioural effects of two benzodiazepines (chlordia-
zepoxide and diazepa~) as well as another antianxiety drug -
meprobromate. He found that only 12 percent of the st~dies 
were carried out on patients. He writes that "this paucity 
of studies directly relev§nt to clinical practice should·be 
a matter of clinical concern." (p.612). 
Significant effects on performance had been reported in. 
about one third of the specific measure employed in the 
studies with the benzodiazepines. When .the benzodiaze-
pines were administered significant impairment occurred 
five times as often as facilitation (27 percent compared to 
5 percent). He classified the ~easures administered in 
the various studies into categories. Then for·each 
measure he tallied the instances of significant impairment 
... 
or facilitation of performance and the instances of nons·ig-
nif icant effects on performance. The percentage of signi-
ficant findings were considered to constitute an
1 
index of 
sensitivity of each measure of drug effect. The most 
sensitive tests in the benzodiazepines studies were: the 
pegboard test, learning paired associ~tes, the digit 
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symbol substitution test, critical flicker fusion thresh-
hold, choice reaction-time and tapping speed. · For example, 
out of the seven occasions when the digit symbol substitu-
tion test was administered significant impairment was 
found on five occasions. 
In general McNair criticizes the studies of the effect of 
antianxiety drugs on human performance; "Almost two decades 
of laissez-faire research in the area have yielded no 
adequate; systematic data base for meaningful inferences 11 . 
(p.615). He stresses that as·· a minimum sci'entists should 
select the best and most appropriate performance measures 
available. 
~i<' 
On e i mp or t an t c r i t er i on :~ -;· '·~~) t h e s en s i t i v i t y 
,.~'tlr'\~!<~ 
of the measures. 
Kleinknecht and Donaldson (1975) reviewed the literature 
describing psychomotor effects of diazepam. Of the 22 
studies cited, only two were based on psychiatrit popul~tion. 
The authors classified the various tasks used to assess drug 
effects into six major groups based on apparent similarity 
of functions tapped. These groupings were: refle~ speed; 
critical flicker fusion threshhold; concentration and 
vigilance; decision making; learning and memory; perceptual 
. ·, 
motor performance. Ref lex speed as measured by simple 
reaction time tasks and tapping speed were not considered 
to be adversely affected by therapeutic levels (up to. 
15 mg/day) of diazepam. Critical Flicker Fusi.on 
Threshhold was sensitive to diazepam and even small 
doses lowered the threshhold. Concentration and 
vigilance as measured by letter 'ancellation and the 
digit symool substitution test showed some impairment. 
There was generally a slowing down of performarice (number 
completed in a given unit time). Various performances 
involving decision making (that is card sorting and 
choice reaction time) showed indications of a dose~rel~ted 
response: two studies using diazepam 10 mg showed no· 
effect, whereas two studies based ori 20 mg reported an 
effect. . Three studies of learning and memory were 
reviewed. Because of the dissimilarity of the tasks 
involved, concluding statements were not offered with 
confidence. There is indication of impairment., It 
. . . 
was s~ggested that the deficit may be in the Eonsolida-
tion process rather than in short term memory per se. 
The tasks grouped under perceptual motor performance 
are tracing ·(where time to complete a t~sk is increased)_ 
and motor skill tasks involving driving simulators 
(where impairment is noted in 6ne out of three studies), 
_and pegboard performance (wher~ impairment, was found). 
Kleinknecht and Donaldson also report that st~dies indi-
cate that s~bjects taking diazepam tend to underestimate 
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the passage of time. In additibn, they are ~nable 
to assess accurately their level of impairment and they 
may, therefore, not compensate adequately for .any induced 
performance deficits. 
Wittenberg (1979 and 1980) critically. re~iews the· effects 
~ 
of benzodiazepines on psychomotor ~erform~nce. He 
concluded that there is no general co~trast in the 
qualitative effect of the various benzodiaiepines., 
The effects of d i a z e pa m , 1 or a z e pa m , ch 1 o, : _;d i a z e pox i de 
and nitrazepam are basically similar. In order to 
summarize the effects of the benzodiazepines, he classi-
fied the vafious tests according to whai he judged to be 
t he es s en t i a 1 n at u re of the opera t ion me a s u red . · . In 
the studies he reviewed there were no instances where· 
the benzodiazepines improved performance. The 
' '•" 
detracting eff.ect was dose related. Less· impairment 
was found at low doses than at higher doses. This con-· 
clusion is also discussed by Greenblatt ~nd Shader .(197~) 
in their review of the psychomotor effects bf the 
benzodiazepines. They. write: 
"reduction of anxiety often occurs after· 
single doses of 5 to 20 mg of chlor~dia­
zepoxide or 2 to 4 mg of diazepam~doses 
which do not consistently produce intel.-
lectual and motor impairment in the 
laboratory. In some individuals, however,. 
daily doses of 60~ to 100 mg of chlordia-
zepo~ide or 30 to 40 mg of diazepam are ·· 
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necessary to reduce anxiety or agitation. 
Clearly, such patients should be cautioned· 
regarding the possible hazards of high 
dosage. 11 (p.179). 
Wittenborn grouped the various tests into 16 categories 
of psychomotor function. He then ranked them in order 
of the relative incidence Of impairment. This is the 
ratio between the number of studies ~hawing impairmerit 
in a given function and the number of studies that 
tested the respective function and this ratio i~ also 
known as the sensitivity of a function. 
The most sensitive functions (showing impairment in 
most instances of assessment) were critical flicker 
fusion threshhold, memory, the digit symbol substitution 
test, cancellation and card sorting. 
Hindmarch (1980) discusses psychomotor function and how 
it is affected by psychoactive drugs~ His paper 
also includes a crinsideration of .studies that a~sess 
the initial effects of the 1,4 benzodiazepines on per-
formance in volunteers. In the Section on psycho-
motor performance, I have already discussed his approach 
to considering psychomotor function in terms of various-
. ' . 
components and he lists the tests which assess the 
variou~ components which have been sensitive to a wide 
r~ng~_of psychoactive drugs in general. This is shown 
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. . 
in summary form in Figure 2 on Page 14 of this 
introduction. In doing this he includes those 
studies that assess the initial effects of the 1;4 
benzodiazepines on p~rformance in volunteers. His 
findings are similar to Wittenborn 1 s conclusions. 
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In general one can conclude that the 1,4 benzodiazepines 
have a dose-related detracting effect on. performance in 
volunteers during their initial one to three d~ys bf medi-
cation. Assessments that have been shown to be relatively 
sensitive in detecting this impairment ar~ the digit sy~bol 
s~bstitution test, letter cancellation tests~ critical 
flicker fusion threshhold, verbal learning and memory tests, 
pegboard test, card sorting and choice reaction time. It 
should be noted that impairment is general)y but not always 
found on th~se tests. For example, Witt~nborn (1979) 
stat~that in the ten instan~es he reviewed which used the 
digit symbol substitution test impairment was found in 
six out of ten applications. 
3.2 PATIENT STUDIES WITH THE 1,4-BENZODIAZEPINES 
A number of reviewers have comme~ted on the lack of 
~tudies that assess the effect of the 1,4 benzodiazepines 
on patients. 
McNair (1973) reviewed st~_dies which investigated the 
effect of anti-anxiety drugs on human performance and noted 
that only 11% of these involved patients. He writes that 
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it is startling that, considering the widespread use of anti-
anxiety agents, we have so little directly rele~nt clinical 
informatjon about the effects on performance of the drugs 
in patients. Kleinknecht and Donaldson (1975) in their 
review paper on the effects of diazepam on performance 
write: 
11 Although diazepain is typically given only to 
medical, psychiatric, or dental patients, .17 
of the 23 studies reviewed used young, 
"normal"~ healthy, volunteer subjects, 
primarily male" (p.403). 
The studies that researched the effects of the 1,4 benzodia-
zepines on psychomotor performance in patients will' now be 
considered. This will be done to ascertain if the effects 
found differ from those found in volunteers. ·Thus ·the 
studies will be considered briefly:that is the specific 1,4 
benzodiazepines used, the specific psychomotor tests utilized 
and whether impairment was reported on those tests will be 
indicated. 
Silverstone (1973) found that pursuit·rotor performance· 
was not impaired by either diazepam or lorazepam. Bond; 
James and Lader (1974) assessed pat~ent's performan~e on 
th~ digit symbol substitution test, card sorting, ~uditory 
. . . 
reaction time, key 'tapping, symbol copying·~·- Glbs:on .S.pi ral 
.·, 
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maze, a cancellation task, arithmetic tasks and tachisto-
scopic recognition of numb~rs. The l·,4 ben~odiaz~pi.nes 
used were diazepam,t~l~rdiazepoxide and medazepa~. The 
only impairments found were on the ~Gibson spiral maze for 
\~ . ' 
paitents taking diazepam or chlordiazepoxide but not in 
·those taking medazepam~. 
Tansella, Zimmermann-Tansella, and Lader (1974) fo~nd that 
N-desmethyldiazepam impaired performance on the digit 
~~ymbol ·substitution test but not on card sorting. Mal pas, 
Legg and Scott (1974) found that hitrazepam did not impair 
performance on either the digit symbol substiiut~on test or 
on card sorting. Salkind and Silverstone (1975) found· 
that flurazepam did impair performance on auditory r~action 
time but di~ not impair performance on key tapping ~nd the 
pursuit rotor task except at higher doses. 
Saario, Linnoila and Mattila (1976) found impaired 
performance in patients given diazepam on ~hoice re~ction 
time, critical flicker fusion, a tracking task; proprioception 
and auditory reaction time. Uhlenhuth et al~ (1977) found 
that diazepam impaired choice reaction time. Dureman, 
Malmgren· arid-Norman (1978) assessed the effect of clorazepate 
on critical flicker fusion, car dri~ing in a simulator and 
on a bead and needle task. No impairment was reported. 
Zimmermann-Tansella, Tansella and Lader (1979) found that. 
diazepam impaired performance on card sqrtini the Gibson 
spiral maze, cancellation tasks and key tapping. Simple 
, 38 
and choice reaction, the digit symbol substitution test, 
symbol copying and arithmetic performance were not impaired. 
Church and Johnson (1979) reported impairment on the digit 
symbol substitution test and choice reaction time but no 
impairment on digit span performance in patients given 
f lurazepam. Saxena, Singh and Porter (1980) found that 
both lorazepam and diazepam impaired choice reaction time 
and key tapping. Linnoila, Erwin and Logue (1980) found 
no impairment in patients who were given flurazepam and 
who were assessed on simple reaction time, continuous 
performance, visual vigilance and digit span performance. 
Salkind, Hanks, and Silverstone (1979) found that patients 
·, 
taking diazepam had impaired performance on the digit 
symbol substitution test but not on the purs~it rotor test. 
Paitents taking clobQzam showed no impairment on either of 
the tests. This study will be considered ~gain when the 
effects of clobQ.zam on paitent's 'performance are discussed. 
An overall consideration of these studies shows certain 
trends. The volunteer studies showed that impairment of 
performance is dose related. Higher doses are more likely 
to produce impairment. A similar trend· is .found in patient 
studies. For example Salkind and Silve~stone (1973) 
showed that 30 mg flurazepam, and nbt 15 mg, significantly 
i~paired performance on both the putsuit rotor test and the 
tapping speed ·test. 
The tests that are sensitive to detecting impairment in 
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volunteer studies are also the most sensitive tests in 
detecting impairment in patients .. However, the number 
of significant impairments in performance that ar~ reported 
is less than in volunteers. This important conclusion can 
be clearly highlighted by considering the results of studies 
that included the digit symbol substitution test. It has 
already been noted that Wittenborn (1980) in his review of 
volunteer studies reported that in ten applications'of the 
digit symbol substitution test significant impairment was· 
found on six occassions. In the patient studies which I 
reviewed I found eight applications of the digit symbol 
substitution test and impairment was found in only two.of 
these applications. 
One possibke explanation for the lesser fr~quency of signi-
ficant impairment found Jn patients is t~e effect brought 
about by their lowered anxiety level as a result of 
benzodiazepine treatment. A previous section of ·the 
' . 
introductio~discussed how too high a level of anxiety ~an 
impair performance and a decrease in anxiety level can. 
result in impfoved psychomotor performance in patients thus 
' . 
offsetting the impairment of performance brought about by 
the sedative effect of the benzodiazepines. 
3.3 THE EFFECTS OF CLOBAZAM ON PSYCHOMOTOR PERFORMANCE 
The studies that have assessed the effect of clobazam on 
psychomotor performance in volunteers will now be considered. 
Since the research investigating the psychomotor effects of 
clobazam on volunteers in relatively recent no co~pr~hensive 
reviews .exist as yet (unlike the 1,4 benzodiazepines were a 
number of reviews exist). This section will therefore 
consider the various specific studies in more detail than 
was done for the 1,4 benzodiazepines. 
The first study reported was conducted by Berry et al. 
(1974). They conducted two studies. The first w~s after 
a single dose where the alternatives were clobazam 10 mg 
alone,. clobazam 10 mg plus alcohol, alcohol alone, placebo, 
and diazepam 10 mg. This single-dose regimen was given 
at weekly intervals using a latin square design such that 
each subject received each treatment once. At hourly 
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intervals after treatment for up to six hours the subjects 
were tested for braking reacting time on a. driving· simulator, 
pursuit rotor performance and arithmatic performance. 
Clobozam did not increase braking reaction time when 
compar~d with placebo, but diazepam 10 mg did produce a 
siginificant increase at 1-3 hours after ingestion. Pursuit 
rotor performance was significantly impaired one and two 
hours after dosage with diazepam and after t~o hours with 
clobazam. Whether these changes on pursuit rotor were 
reJ<t,tive to placebo was not indicated. Arithmetic 
performance was npt) significantly affected by diazepam or 
clobazam. In the second part of the study, four subjects 
rec~}Jved clobazam 10 mg three times daily for two weeks and 
two subj e ct s re c{i~v e d d i a z e pa m 5 mg three t i me s d 'a i\l y for 
. ,____ '- ........... ' 
two weeks. Assessments were made before and after the 
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final dosage on day 14. After this period of continuing 
treatment there was an improvement in psychomotor performance, 
particularly after treatment with clobazam. 
Since no placebo control was used in the repeated dose 
study the results cannot be interpreted with confidence. 
The enhanced psychomotor performance could be due to an 
unidentified practice effect. This whole study can also 
be criticized for being very briefly reported and for using a 
very small sample size. In addition the dosage of 
10 mg diazepam used in the first part of the study is not 
equivalent in potency to 10 mg clobazam; 5 mg diazepam is 
the equivalent dosage to 10 mg clobazam. All these 
factors indicate that this study should be interpreted with 
caution. 
Borland and Nicholson (1974) investigated the immediate 
effects on human performance of clobazam (20 mg), chlordia-
zepoxide hydrochloride (20 mg) and diazepam (20 mg). 
Choice reaction time and adaptive tracking performance 
(similar to the pursuit rotor test) were assessed. Five 
healthy male subjects were used each receiving all three 
medications on different occasions. Each drug was 
ingested at 09.00h and performance has measured at 09h 30min 
(0.5h), llh 30min (2.5h), 14h 30min (5.5h) and 18h 30min 
(9.5h after ingestion). 
With diazepam decrements in performance on adaptive 
tracking were observed at o,5h and 2,5h. ·With clobazam 
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performance at individual times did not differ significantly 
from control, but there was evidence of an improvement in 
performance during the day. There was no evidence of im-
paired :performance on adaptive tracking after chlordiaze-
poxide hydrochloride. Reaction time w~s slo~ed at 0,5h, 
and 2,5h and 9,5h after diazepam and at 0,5h and 2,5h after 
chlordiazepoxide hydrochloride. No changes in reaction 
time were observed after clobazam. 
This study showed that clobazam unlike diazepam and chlor-
diazepoxide hydrochloride did not have any detracting 
effect on adaptive tracking or on reaction time. 
Hindmarch and his co-workers have carried out numerous studies 
on the psychyomotor effects of clobazam. 
Parrot and Hindmarch (1975a, 1975b, 1977, 1978) investi-
gated the effect of clobazam and other drugs on critical 
flicker fusion threshhold and choice reaction time. They 
reported that unlike the l,4benzodiazepines clobazam did 
not cause a lowering of critical flicker fushion th~eshhold. 
There were no significant changes in CFF threshhold produced 
by either 10 mg or 20 mg clobazam. In the choice reaction 
time tasks the subjects were presented with a stimulus 
light paired with a buzzer and had to respond by pressing 
the appropriate colour coded key which then terminated both 
stimulus light and buzzer. Responses were measured under two 
buzzer conditions; (a) where the buzzer was soft toned and 
mainly informative in function and (b) where the buzzer was 
" 
loud and raucous. 
· .. ,. 
.·,;_·.· 
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A decrement in performance was found in the first condition 
but not in the second. The authors explain these 
differential changes in response speed as depending on the 
anxiolytic properties of clobazam. They hypothesize that 
by reducing state anxiety the overall drive or motivation 
to respond quickly is lowered. In the low reinforcement 
condition (soft toned buzzer) speeds were therefore 
reduced but in the high reinforcement condrtion (loud 
buzzer), where incentives to respond quickly are intrinsic 
to the task, response speeds were as fast as they would be 
normally. A similar differential effect was found for 
f lurazepam. Nitrazepam, however, reduced reaction time 
at both high and low reinforcement conditions. This the 
authors write is probably due to the sedative as opposed 
to anxiolytic activity of the drug. 
These studies indicated that clobazam has far less of a 
detrimental effect on CFF threshhold and choice reaction 
time. 
Hindmarch, Hanks and Hewatt (1977) assessed .the effects cif 
clobazam (20 mg) on car-driving ability, choice reaction 
time, and the digit symbol substitution test. No 
significant detrimental effect on any of the performance 
measures was found. However, an examination of the raw 
·data from two of the ten subjects showed a marked decrement 
in both ·car-driving ability and psychomotor performance. 
The authors note that this noticeable interference with car 
driving performance in individual cases was not associated 
with 1 en gt h ,' of car d r i vi n g exp er i enc e , or person al it y or 
any other easily identifiable factor, and can only be· 
attributed to a specific "sensitivity" of certain 
individuals to the drug administere~. since the .impairment 
of car driving ability and of psychomotor performance was 
not generally found. 
Hindmarch and Parrott (1978) and Hindmarch (1979) again 
showed that clobazam did not impair choicd reaction time 
or lower critical flicker fusion (CFF) threshholds. 
Furthermore, these two studies pro~uced evide~ce that 
clobazam in fact elevates CFF threshholds. In the 1979 
study ten anxiety rated volunteers received 10 mg clobazam 
three times a day for a period of five days. Measures 
were taken the morning of the first, fourth and fifth 
days. The CFF threshholds were significantly elevated 
on the fourth and fifth day of the study; +0,8 Hz, .. 
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p less than 0' 01 and + 1 , 6 Hz, p less than O,OJ respectively. 
These results led Hindmarch to hypothesize that the anxio-
lytic activity of clobazam could be due, in part at least 
to its ability to increase critical flicker fusion thresh-
holds, that is central nervous system arousal and inter-
grating ability. This elevation that Hindmarch found is 
in sharp contrast to the reduction of CFF threshholds 
produced by the 1,4 benzodiazepines. In additi-0n in the 
1978, Hindmarch and Parrott also found that clobazam did 
not impair performance on a concept identification test. 
I 
I 
I 
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Hindmarch (1979) once again showed that clobazam did not 
impair CFF threshhold, choice reaction time and stabilometer 
performance. In this study CFF threshholds were signifi-
cantly elevated. Hindmarch and Parrott (1980) again 
confirmed that 10 mg and 20 mg doses of clobazam did not 
impair choice reaction time. The 10 mg dosage had no 
effect on CFF threshhold.. However~ the 20 mg dosape 
resulted in a significant reduction in CFF threshhold. 
This is the only occassion that clobazam resulted in 
sigb'/ificant reduction in CFF threshhold air other research 
findings have shown clobazam to either not effect CFF 
threshholds or to result in significant elevation of CFF 
threshholds. 
Hlndmarch and Parrott (1979) measured the effects of 
clobazam (30 mg) and di potassium ch(orazepate (15 mg) a 1,4 
benzodiazepine·'. on choice reaction time, critical flicker 
/ 
fusion (CFF) threshhold, a concept identification task and 
·mental arithmetic. Clobaza~ did not impair performance on 
any of thes~ tasks. Once again it was found that clobazam 
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was associated with a significant increase in CFF threshhold. 
Dipotassium chlorazepate produced a slight depression of CFF 
threshhold,)when compared to placebo but the results were 
not significant. In the concept identification task dipo-
tassium chlorazepate significantly increased the response 
latency for the correct solution of the easy concepts, 
however, there was no impairment at the more dirficult 
level. The choice reaction time and mental arithmetic 
taks were not impaired by di potassium chlorazepate~ 
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Hindmarch and Gudgeon (1980) investigated the effect of lora-
zepam (1 mg three times daily) and clobazam (10 mg three times 
daily) as compared to placebo on twelve female volunteers. 
The medication was taken for three days and testing was 
carried out on the morning of the fourth day after taking 
a further single dose of medication. The subjects were 
assessed on concept identification task, motor manipulation 
measured on a pegboard, mental arithmetic tasks, letter 
cancellation tasks and five car handling tasks. In 
addition subjective ratings of alertness were obtained on 
visual analogue r~ting scales and side effects were recorded. 
The concept identification and pegboard tasks were not 
·affected by either clcibazam or lorazepam. Tn~ mental 
arithmetic tests involving the serial subtraction of numbers 
showed a significant difference between·the three treatment 
means forthe time taken to sequentially subtract either 
I 
twenty 3s or 7s from a five digit number. Lorazepam 
impaired performance for the serial subtraction of 3s or 
7s whereas clobazam impaired performance only in the one 
task the subtraction of 3s. 
In the letter cancellation task the time taken to cancel 
either l, 2, 3,or 4 letters from pages of random letters 
was impair~d by lorazepam for 2 and 4 letter cancellations 
and by clobazam only for 4 letter cancellations. 
Lorazepam impaired performance on four of the five driving 
tests whereas clobazam did not result in any impairment on' 
the car driving tests. Lorazepam was perc~ved as 
resulting in subjective feelings of drowsiness as measured_ 
by the visual analogue seal~ and was also associated with 
significantly more sedative side effects than clobazam. 
Thus although clobazam did cause some impairement (serial 
subtraction of 7s and cancellation of 4 letters) it 
produced far fewer incidences of impairment and far less 
subjective evidence of sedation. 
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·Wittenborn, McGrough and Nash (1979) compared the effects 
of diazepam (5 mg three times daily) ·and .clobazam (10 mg 
three times daily) against placebo effects over the course 
of the initial day of medication. Tests were administered 
at hourly intervals and the data were analyzed from the 
standpoint of contrasts at each session and from the stand-
point of trends that occurred during the course of the day. 
Seven measures were taken. Four of these measures, the 
digit symbol sybstitution test, a test of numerical ·ability, 
a time estimation test and a simple vigilance test, provirled 
no significant distinction among the three medication 
groups. The spontaneous perceptual reversals reported by 
the subject, while gazing at the Necker cube for one minute 
were counted for each of the ten hourly sessions comprising 
the daily sequence. The pattern of acquisition over the 
day was impaired in the diazepam group. In ·the complex 
vigilance task there was significant impairment in the 
diazepam group. The clobazam group did not show any 
impairment in fact there were indications of enhancement 
of performance as shown by a significant general trend 
toward fewer incorrect responses. The other test of 
performance involved the assessment of equilibrium by a 
balance beam procedure. In this test there was also an 
indication of enhancement of performance in the clobazam 
group which was associated with relatively fewer missteps. 
Commenting on these results the authors wrote, 
11 i t is suggested th) 5 mg three times daily 
may be near the threshhold for psychomotor 
detraction during the initial day of dia-
zepam medication and that clobazam 10 mg 
three times daily has no appreciable de-
tracting, and may have some enhancing 
effects" (p.75). 
The various studies on volunteers indicate that clobazam 
is virtually free ·Q:"f,)detrimental effects on psychomotor 
performance. Those tests adversely effected by 1,4 
benzodiazepines are generally not adversely effected by 
clobazam. Specifically critical flicker fusion thresh~ 
hold (CFFT) is consistently significantly lowered by the 
1,4 benzodiazepines, for clobazam Hindmarch and his 
associates have shown five instances when CFFT was not 
changed, one instance where CFFT was significantly lowered 
(after 20 mg of clobazam a fairly high dose and five 
instances of significant elevation. Another exception 
to these general findings (of clobazam not having a 
detrimental effect on performance) was in the Hindmarch, 
Hanks and Hewett (1977) study where two of the ten subjects 
showed impaired performance. This finding could only be 
explained by attributing the impairment to a specific 
11 sensitivity 11 of these two individuals. This "sensitivity" 
has not been reported in any other studies. 
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Although research indicates that clobazam does not have 
the objective indication of sedation (impairment in 
performance) there is evidence that drowsiness (cons.idered 
as a subjective indication of sedation) occurs in patients 
receiving clobazam. In clinical trials assessing 
clobazam's anxiolytic effects drowsiness is the most 
commonly reported side-effect (Koeppen, 1979). Three 
times as many patients report drowsiness when treated with 
clobazam (about 17%) relative to those receiving placebo 
(about 6%) (Brogden et al., 1980). In double-blind 
studies comparing clobazam with diazepam the overall 
incidence of reported drowsiness is very slightly less for 
clobazam. In discussion on Ban's (1979)paper Stonier 
comments that drowsiness reported by patients recei·ving 
clobazam may reflect something other than sedation. Most 
clinical trials simply note the incidence of drowsiness and 
in order to investigate this phenomenon it is important to 
gain a more precise assessment by ascertaining the degree 
of drowsiness experienced by the particualr patient. 
Only two studies have investigated psychomotor performance 
in patients receiving clobazam., Doongaji et al. (1979) 
conducted a double-blind clinical trial on out-patients 
· d i a g no s e d a s 11 an x i o u s n e u rot i t s 11 by two i n dependent 
psychiatrists. The patients responded ~qually:~ell in 
terms of anxiety reduction to clobazam (30 - 40 mg daily) 
and to diazepam (15 - 20 mg daily). Clobazam was superior 
to diazepam on the 15th day of the trial on the hand steadi-
ness test (a measure of motor co-ordination), although this· 
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difference was not detected at any other evaluation perio~ 
(measures were taken on days 8, 15, 22 and 29). It was · 
especially patients with high initial error· scores who 
I ' ·, 
showed improved performance on clobazam the difference was 
significant on day 15 of the trial. 
Salkind, Hanks, and Silverstone (1979) conducted a double~ 
blind clinical trial comparing clobazam, diazepam and placebo 
in anxious patients attending a general practitioner. Both 
clobazam and diazepam significantly reduced anxiety whe~eas 
placebo did not. Two measures, the digit symbol substitu-
tiion test (DSST) and the pursuit rotor test, were 
assessed prior to treatment and after two weeks of .treatment. 
they compared the variation in performance in the three 
~, 
groups. The placebo group showed a significant.improve-
ment in performance on both tests due to learning effetts. · 
The clobazam group showed an improvement in both tasks but 
significantly so only for the DSST~ The ~iaiepam gro~p 
performance did not change. This indicates that diazepam 
produced an impairment in performance (objective sedation) 
in both the DSST and the pursuit rotor test that negated 
the learning effect seen in the placebo group. T~e authors 
do not comment on the lack of significant improvement in 
the clobazam group on the pursuit rotor test. Since the 
placebo group showed significant improvement on this test 
and therefore one can conclude that clobazam also enduce~ 
impaired performance on the pursuit rotor test. Clobazam 
of course did not produce impaired performance on the OSST. 
4. AIMS ANO OBJECTIVES OF THE PRESENT STUDY 
Both the studies investigating the effect of clobazam on 
patient's performance measured only limited aspects of 
psychomotor performance and were mainly concerned with 
anxiety changes. Both compared clobazam to diazepam and 
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there is a clear need to make a comparison with lorazepam, 
another widely prescribed 1,4 benzodiazepine (Hedges et al., 
1971; Siassi et al., 1975 and Mccurdy; 1979). Neither 
the Doongaji nor the. Salkind study referred to previously 
included a short-term (after 24-48 hours of treatment) 
assess~~nt. This is the period when impairment of perfor-
mance due to sedation is very likelj to be shown (Wittenbo~n, 
1979a). 
The present study then aims to systematically investigate. 
the effects of clobazam and lorazepam relative to placebo 
on patients' performance. A shorter-term assessment (after 
two days) and a longer-term assessment (after nine days of 
treatment) will be included to ascertain if ther~ are any 
changes in drug effects on performance over time. This· wi 11 
allow drug accumulation and/or adaptation effects to be ascer-
tained. A number of carefully selected performance measures 
will be used, one important selection criterion being that· 
these measures should have a relatively high sensitivity in 
detecting impairment in persons (non-anxious volunteers) 
receiving. a 1,4 benzodiazepine re·lative to those.recelvtng ·a 
placebo. Another important criterion being that the 
total battery of. measures should assess the whole range 
of the important components of psychomotor performance·. 
The primary emphasis will be on performance effects~ but 
anxiety changes and the incidence and degree nf drowsiness 
will also be investigated. The results of the study will 
have implications as to the generalization of previous 
research findings on drug induced performance changes in 
volunteers to patients. 
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5. . METHOD 
-~ 
5. l SUBJECTS 
The patients were selected from those patients who had 
been prescribed a 1,4 benzodiazepine by a doctor at 
Retreat Day Hospital. A day hospital was chosen due to 
the availability of patients and the greater likelihood 
that the patients would return for subsequent assessments 
as most would live relatively near to the hospital. All 
patients assessed as needing 1,4 benzodiazepine trea~ment 
were referred to the investigator either by a doctor or 
by the pharmacist. 
Patients who were excluded from the study w~re: (a) those 
that were on concomitant psychotropic medication or any 
other medications likely to affect psychomotor performance, 
(b) patients with alcoholic problems, (c) patients who 
have taken tranquillizers over the last three weeks, (d) 
patients under the age of 18 or over the age of 65. 
In total, 120 patients were started on the. trial medication. 
It was hoped that 70 to 80 patients would co~plete the 
trial (this allows for a 33,3 to 42% drop-out rate), so 
that on completion of the trial there wi 11 ·be approximately 
23-27 patients per treatment group. The sample size of 
70 to 80 was ascertained by considering various statist1cal 
and practical cri te ri a (Gil be rt, 1977). 
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5.2 APPARATUS 
The main criteria. on which the laboratory.measures which 
would assess aspects of psychomotor performance were 
selected, was that previous studies have shown that,the 
measures have a relatively high sensitivity to detecting 
drug (1,4 benzodiazepine) - placebo differences, i.e., 
significant impairment relative to placebo. Anothe~ 
important criterion was that the tests take a fairly short 
time to complete, so as not to take up too much of the 
patient's time. The tests were al~o selected so that the 
total battery would assess a variety of important aspects 
of performance~ In terms of the tests di~cuss~d in t~e 
introduction (p.14 and p.21 ); one test was selected 
·that assessed sensory function and sensory processing 
ability - that is the Digit Symbol Substitution Test 
(DSST) which involves the recognition phase of infor~ation 
processing: One test was selected that assessed central 
Nervous System Integration (Alertness) - that is the · 
assessment of Critical Flicker Fusion Threshhold (CFFT); 
One test was selected that assessed central processing 
ability - that ts the Inglis Paired Associate Learning 
Test (INGLIS) which involves verbal learning and ~emory; 
one test was selected that assessed motor function and 
behavioural coordination - that is the Purdue Pegboard Test 
(PPT) which primarily involves the coordination co~ponent 
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of motor function and one test was selected which assess~s 
overall psychomotor performance - that is the Choice Reaction 
Time (CRT) test. 
·. \ 
5.2.1 The Digit Symbol .Substitution Test 
This is a performance sub-test of the Weschler Adult · 
Intelligence Scale. The test assesses the ability to 
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sustain concentration as well as a number of other aspects 
including motor coordination, visual acuity and speed of 
performance {Matarazzo, 1972; Mirsky and Kornetsky, 1964). 
The reliability of the test has been established in studies 
assessing the reliability of the W.A.l.S. · (Matar~zzo, 1972). 
5.2.2 Critical Flicker Fusion Theshold (CFFT): 
This is the frequency at which the patient perceives a 
flickering light as a stable non-flickering light.source. 
. . ' . . 
The subject was required to discriminate flicker in one 
of a set of four light-emitting diodes as the frequency 
changes from a lower to a higher frequency. This measure 
is viewed as giving an inrli~ation of cortical arousal and 
. . 
i n t e g r a t i o n ( H i n d ma r c h , l 9 7 8 ) • ~.d 11 c e p u p i 1 s i z e e f f e c t s 
CFFT an artificial pupil was used to control for pupil 
size (Smith and Misiak, 1975). This consists of spectacles 
which are movable perspex transluscent discs with two 
millimeter holes drilled in each lens. The CRT and ·cFFT 
measures were carried out in darkened conditions whith 
. . 
were kept uniform for all assessments. The CRT was carried 
out prior to the CFFT and thus patients were given time 
(about 15 minutes) to adapt to the semi-darkness •. ThJs 
period of dark adaptation is important (Smith and Misiak, 
1975). The patients were given two prdctice trials 
' ' . 
and three actual trials. The mean of the three trials 
was taken as the measure of CFFT. 
5. 2. 3 Memory Performance 
Memory performance on short-term tasks has been shown 
to be impaired in persons receiving 1 ,4 benzodiazepines 
and memory performance has not been investigated with 
clobazam. The memory test would be one that took a 
brief time to administer. McNair (197j) iri his review 
on the effects of antianxiety drugs on human performance 
noted that learning paired-associates was a measure which 
had high sensitivity in detecting drug effects.. On con-
sidering these criteria it was decided to use the Inglis 
Paired-Associate Learning Test (Inglis, 1959). This test 
has been shown to be sensitive· to memory impairments and 
to be relatively independent of general inielligence level 
(Inglis, 1959; Caird and Sanderson, 1962). The test was 
designed to assess memory impairment in elderly patients. 
It is viewed as a test of the acquisition phase ot learning. 
The patients were read three pairs of word~. 
They were then given the first word of a pair as a 
stimulus and were expected to respond with the correct 
second word as a response. The first words of the pairs 
are presented one by one in a random order. The material 
was presented in this way until the patient got three 
consecutive correct responses for each pair. Inglis, 
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constructed two equivalent sets of pairs of word~. 
Since there are three assessments in this study a third 
equivalent set of three pairs of words was constructed 
on the basis of similarities in abstractness-concreteness, 
imagery values, word association values, and Thorndike-
Lorge frequency of the nouns (Paivio, 1968). The three 
forms of the test are in Appendix 2. 
5.2.4 Purdue Pegboard Test 
This test is primarily a measure of coordination and 
dexterity. It involves placing small pins into a set 
of holes. Patients did three separate tasks. The first 
involved placing as many pins as possible into a row of 
holes in 30 seconds with the preferred hand. The second 
involved placing pins in two rows of holes with both 
hands for 30 seconds. This third involved constructing 
assemblies of pins, collars and washers with both hands 
for 90 seconds. Adequate reliability has been ascertained 
for this test (Tiffin, 1968). 
5.2.5 Choice Reaction Time (CRT) 
This will be measured on the Leeds Psychomotor Tester 
which is a portable apparatus capable of measuring 
critical flicker fusion threshold and choice reaction 
time. The patt~~t responds as quickly as possible mo~ing 
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their index finger of the preferred hand to extintuish 
one bf six stimulus lights ~hich illuminate on a random 
basis. The test involves a decision making·componeht 
and speed. (Kleinknecht and Donaldson, 1976). There· 
were 10 practice trials, and then 20 test trials, the 
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mean of which was taken as the performance measure. ·The 
positioning of the response panel with respect to the sub-
ject's finger and hand was kept constant so that repeated 
measures .would be reliable (Hindmarch, 1975a). The stimulus 
light in the choice reaction time task are fairly widel~ 
separated so that a high level of sustained attention was 
needed to maintain an optimum performance level (Hihd~arch, 
1978). 
5.2.6 Assessment of Anxiety 
The Hamilton Anxiety Rating Scale was used to assess 
anxiety (Hamilton, 1958). This i~ a rating scale of .high 
reliability which is used in much of the research on 
antianxiety drugs. It consists of ascertaining by 
interview the occurrence and degree of severity of 
psycho 1 o g .i ca 1 and phys i o 1 o g i ca 1 · man i f es tat i on s of an x i e ty 
states (Appendix 4). In addition, a vis~al analogue 
scale of anxiety which the patient filled in by placing 
a cross on a 10 centimetre line according to the'ir degree 
pf anxiety-calmness, was used (Appendix 5). Visual 
analogue scales are viewed by some investigators as use-
ful measures of mood states (Aitken, 1969; Zealley and 
Aitken, 1969). A visual analogue scale of the patient's 
motivation in their daily activities was also given 
(Appendix 6). This is in order to explore possible 
motivational changes during drug treatment. Wittenborn 
(1979a & b) noted that clobazam may induce motivational 
enhancements. Luria (1975) has reported adequate 
reliability and validity of visual analogue scales. 
5.3 PROCEDURE 
Once a patient had been referred to the investigator by 
a pharmacist or a doctor the investigator assessed if 
the patient was interested and suitable for inclusion 
in the study. The nature of the study was explained 
to the patients in an appropriate way~ They were told 
that they would receive medication that would help them 
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to relax and that should help to alleviate their particular 
complaints; for example insomnia and headaches., They 
were told that a possible detrimental effect of the 
treatment is that some patients experience mild transient 
drowsiness and that they should avofd alcohol over the nine 
days that they are taking the capsules. In addition, they 
were informed that their ability to perform quickly would 
be assessed. If the patient agreed to participate in the 
study, they were told that they would be compensated for 
travelling expenses. Informed consent in writing was 
obtained from all patients (Appendix 3) .. The informed consent 
form was drawn up on the basis of the recommendations in 
the Declaration of Helsinki (The World Medical Association, 
l 97 5) . 
If a particular patient had not improved after the nine 
days of treatment they were if necessary given their 
original prescribed medication. Previous research has 
shown that many patients (about 40%} with anxiety ~roble~s 
do respond to a placebo favourably (Greenblatt· and Shader, 
1974}. This research has been passed by the Ethical 
Review Committee at the University of Cape Town Medical 
School. 
The procedure of the study was the standard procedure fdr 
conducting a clinical trial (Taber, 1969}. The patients 
were allocated randomly and on a double-blind basis to 
either of the following treatments: (a) 10 mg. clobazam 
capsule twice a day, (b} a 1 mg. lorazepam capsule twice 
a day, and (c} 1 placebo capsule twice a day. (10 mg. 
of clobazam is equivalent to 1 mg lorazepam (Koeppen, 
1979)). All capsules looked identical and were enclosed 
in coded containers. The containers were coded in groups 
of three. The first group is Al, A2 and A3; the second 
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is Bl, B2 and B3 - and so on. The type of drug contained in 
each group of three containers had been randomized. The 
first patient received Al, the second A2 and so on. The 
investigator and patient were thus blind to the type of 
medication dispensed. The containers were made up and coded 
by the firm funding the study, Roussel Laboratories South 
Africa. A copy of the code was kept by the head pharmacist 
at the hospital in case it is necessary to know what 
treatment a particular patient is receiving for urgent 
medical reasons (Taber, 1969}. 
The patients were assessed before starting treatment, at 
two days after starting treatment, and again at nine days·, 
when treatment stopped. A particular patient was assessed 
at the same time of day for each visit, for example early 
in the morning for all three assessments so as to control 
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for time of day effects on performance. Th~ patients were 
asked not to drink alcohol or smoke cigarettes or to drink 
more than one cup of coffee on the days on which they are 
assessed as this would effect their psychomotor performance 
(Lewis at al, 1969; Barlow and Baer, 1967). If a particular 
patient had been smoking or drinking alcohol or excessive 
coffee on the initial day of attending the hospital they 
were not assessed on that day but on the next day. 
t 
Once the initial biographical information (age, marital 
status, occupation and educational level) was obtained 
from the patient the assessments were administered by the 
investigator in a standardized manner in the following 
order: (a) Hamilton Anxiety Rating Scale, (b) Visual 
Analogue Scale for anxiety, (c) Visual Analogue Scale 
for motivation, (d) Digit Symbol Substitution Test, {~) 
Purdue Pegboard Tests, (f) Choice Reaction Time, (g) 
Critical Flicker Fusion Threshold, (h) Ingiis Paired-
Associate Learning Test. A similar order of assessments 
was used at the two and nine day appointments. The 
occurence and degree of drowsiness (Absent = 0,. Mild = l. 
Moderate= 2, Severe= 3 and Very Severe= 4) was also~. 
noted at the day two and day ~ine assessments. The time 
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taken to complete the assessments was about 45 to 60 
minutes. 
The patients were encouraged to do the.ir best on the 
psychomotor performance tests. This was done in a standard 
manner so as to maintain constant conditions of.motfvational 
instructions throughout the study. The subjects• level 
of motivation is known to effect psychomotor performance 
(Hindmarch, 1980}. 
After the assessment at nine days, five millilitres of 
blood was drawn by a nursing sister. Blood assays for 
clobazam or lorazepam were carried out by the Department 
of Pharmacology, Stellenbosch University at Tygerberg 
Hospital. The method of assay involved electron capture 
detection and gas chromatography and was partly adapted 
from Peat and Kopjak (1979). 
A number of other measures were used to ensure compliance. 
The pati~nts were encouraged to take their cap~ules. At 
the end of the first visit only the necessary dosage of 
•, 
four capsules which would be taken between the initial and· the 
day two appointments was dispensed, to encoura~e the patients 
to return for their day two visit for further medication. 
This made a check on compliance after two days relatively 
easy. The capsules for the next seven days of treatment 
were dispensed after completion of the day two assessments. 
Since there would be an· ad.d·i:tional ten c-apsules beyond the 
. ··.·. 
..... 
14 required for one week of treatment between the second 
and third visits, the patients were asked to return their 
remaining capsules on their third visit.and then these 
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were counted as a further check on compliance. 'In addition, 
the patients were asked about their degree of adherence 
to the twice-a-day dosage ~hedule to ascertain compliance 
(Blackwell, 1976). . , 
After the completion of the final assessmenti and blood 
sampling the patient was given a booklet 11 Coping with 
Tension 11 (Ackerman, 1979) which co~tains some useful 
information including a short description of relaxation 
exercises which the investigator briefly discussed with· 
the patient. 
5.4 STATISTICAL ANALYSIS 
A two-way analysis of variance was used to analyse the 
results on each measure. Factor A is type of drug~ There 
are three levels, placebo, clobazam, and lorazepam. Factor 
B (repeated measµres)is time of assessment. Here there· 
are three levels, before treatment, at. two days (short-term), 
and at nine days (longer-term). Thus the major aims of the 
research, differences between treatments, changes over time 
and the interaction between these two independent variables, 
can be explor~d. 
Intercorrel at ions.' betwee·n the various dependent variables 
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was also explored. Since a number of two way anovas will 
b e c on d u c t e d on d a ta f r om th e s am e s u bJe ct s a more. s tr i n g e n t 
level: of significance (less than 5%) was used to minimise 
the chance of Type I errors. Homogeneity of error variance 
(an important assumption of the anova) was checked. Since 
the number of drop-outs was different in each treatment 
group unequal sample sizes arose. Appropriate statistical 
solutions have been employed to deal with this, that is 
"unweighted means analyses 11 (Gilbert, 1977b) . 
. · ... · .. ·:.'.:- ......... ,· .. : .. . 
. . ".. . .. 
6. RESULTS 
TABLE 1: Details of number of patients, age and sex 
distribution and education level. 
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Type of Treatment Placebo Clobazam Lorazepam 
Initial number of patients 40 40 40 
Number of patients who com-
pleted treatment and whose 
blood assays indicated that 
they were complying with 
treatment 20 27 ·.23 
Age range. 18-63 18-51 20-57 
Median age 35 38 32 
Number of males who com-
pleted and complied with 
treatment 1 ' 4 2 
Median school standard 
passed 5 5 5 
A total of<TI!O patients out of 120· successfully completed 
treatment. The blood assays of these r~o patients i~dicated· 
·-- ' . . 
that they had complied with treatment. 
patients completed their treatments but three patiBnt~ 
had to be excluded from the study because their blood as~ays 
irirJicatE:d·tr1at they had been taking some other form of 
benzodiazepine in addition to the trial medication. Two 
of these patients were in the clobazam group and one in 
·the placebo group. 
As can be seen from Table 1 the. three treatment groups 
are broadly comparable and the slight differences between 
them are not significant. Specifically th~ difference · 
in drop-out rates in the three treatment groups was ~hown 
to be no different from what one would expect by chance 
when a Chi-square analysis (Section 6.3} was carried out. 
The groups were made up predominately of female patients. 
The median school standard passed (Std. 5) was similar 
for each group. The age ranges and median ages of the 
three groups differ very slightly. 
6.1 TWO WAY ANALYSIS OF VARIANCE (WITH REPEATED MEASURES 
ON FACTOR B} 
. 
For clarity of presentation e.achof the vdrio1hl"'• will be 
considered separately. 
6.1.1 Hamilton Anxiety Scale 
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TABLE 2: Mean (± s.d.} Hamilton Anxiety Scale (HAS) Scores. 
Pre-treatment After 2 days After 9 days (BI ) (82} (B3), 
Placebo (A I ) 20,65 (± 3 '9) 14,30 (± 3 •. s) 13' 15 (± 4,4) 
Clobazam (A2) 22,74 (± 4, I) . 15,07 (_t_ 4 ,8) 12,07 (± 5,0} 
Lorazepam (A3) 23,91 ( .!. 4. 3) i:4 ,IH . (" t 3 's) ... 11 , 3 9 '-:!:. 3 '0) 
Bl 82 83 
Pre-treatment After 2-days After 9 days 
FIGURE 4: HAS Cell mean profile. 
The means of the three treatment groups at the three times 
of assessment ·.for the Hamilton Anxiety Scale are shown in 
"-..) 
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Table 2 and illustrated in Figure 4. The cell mean profile 
indicates that there are different trends in anxiety changes· 
in the three treatment groups during the course of treatment. 
The two-way analysis of variance will indicate if these 
trends are significant. 
TABLE 3: Anova summary table for HAS scores. 
Source 
Between subjects 
A (type of treatment) 
Subjects 
Within subjects 
df 
2 
67 
MS 
. 9, 18 
40,79 
F ratio 
0,225 
68 
B (time of assessment) 
AB (interaction) 
Residual 
2 
4 
134 
1959,46 
37,6 
6,95 
282 .• 14** 
5,41** 
x* p.C0,01 
Table 3 shows that the interaction {AB) effect is signifi-
cant (p<0,01) and therefore the main effects cannot be 
interpreted and simple main effects have to be investigated. 
A significant interaction effect implies that there are 
different trends at each level of a particular factor. 
The simple main effect analysis will indicate specifically 
which of these trends are significant. 
. ' ~ 
TABLE 4: Simple main effects summary table for HAS 
Source 
A at Bl 
A at B2 
A at B3 
Within 
B at Al 
B at A2 
B at A3 
Residual 
* p<0,05 
** p < 0'01 
' df MS 
2 57,94 
2 3,45 
2 16,70 
201 18_,23 
2 326,32 
2 817,00 
2 964,70 
134 6,95 
F ratio 
3' 18* 
0' 19 
0,91 
.46,98** 
117,64'k* 
138,90** 
The significant (p<0,05) F ratio for A at Bl (Table 4) 
means that the.treatment groups (A) differed significantly 
from each other in HAS scores at pre-treatment (Bl). The 
specific significant differences will be ascertained by a 
Tukey HSD (honestly significant difference) analysis. 
The s i g n if i cant ( p < O ,'O 1 ) F rat i o s for B ( t i me of ass· es s men t ) 
at Al (placebo), Bat A2 (clobazam) and Bat A3 (lorazepam) 
mean that there were different changes in HAS scores in 
each of the three treatment groups over the course of the 
three assessments. The specific significant differences 
. . 
will be -elucidated by Tukey HSD qnalysis .. ·.These different 
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.. 
trends can be· seen in Figure 4. For example, the 
placebo group has an initial HAS scar~ below the other 
treatment groups but after 9 days of treat~ent it has a 
higher HAS score. 
TABLE 5: Tukey HSO results for A at Bl~ i.e. three 
treatment groups at pre-treatment assess-
ment (Bl). 
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Placebo (Al) Clobazam (A2) Lorazepam (A3) 
Al (20,65)+ 3,80* 5,72** 
A2 (22,74) 
A3 (23,91) 
* p < 0 '05 
** P< 0,01 
. 2 '21 
+ Note the actual means being compared are shown on the left 
hand column of the table - this convention will ·be adopted 
for clarity in all the other Tukey HSD tables. 
Table 5 shows that the mean HAS score ofthe placebo group 
(Al) is significantly (p < 0,05) lower than the mean HAS 
score of the clobazam group (A2), and that the mean HAS 
score of the placebo group (Al) is significantly (p< 0,01) 
lower than the mean HAS score of the lorazepam group (A3). 
The mean HAS of the clobazam group (A2) do not differ 
significantly from those of the lorazepam group (A3) . 
.. 1"\ 
TABLE 6: 
I . 
Tukey HSD results for Bat Al, i.e. three 
assessment times for placebo group (Al). 
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Pre-treatment (Bl) After 2-days (82) After 9-days (B3) 
Bl (20,65) 
B2 (14 ,30) 
B3 (13, 15) 
** p < 0,01 
10,78** 12,73** 
1,95 
Table 6 shows that the mean HAS score in the placebo 
group at pre-treatment (Bl) differs significantly 
(p < 0,01) from the mean HAS score at 9-days (B3) and 
that the mean HAS scores at pre-treatment (Bl) also 
differ significantly (p < 0,01) from the mean HAS 
score ~t 2-days (B2). The mean HAS scores at 2~days -
(B2) do not differ significantly from those at ~-d~ys. 
----- - -- -~------, 
TABLE 8: Tukey HSD results for Bat A3. i.e. three 
assessment times for lorazepam group (A3)~ 
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Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
Bl ( 23, 91) 
B2 (14 .78) 
B3 (11 .39) 
** p < 0,01 
16,62** 22,79** 
6t17** 
Table 8 shows that the mean HAS scores drop significantly 
(p <0.01) in the lorazepam group (A3) from. pre-t.reatment. 
(Bl) to the. 2-day assessment (B2) and continue to ·drop 
significantly (p < 0,01) to the 9-day assessment .(B3) .. 
The change from Bl to B3 is also thus significant 
(p <0.01). 
': 't 
6.1.2 Visual Analogue Scale for Anxiety 
.' .:- .... ; 
··1" 
·~·.· -'' 
TABLE 9: Mean (± s.d.) Visual Analogue Scale ~o~ Anxiety 
(VAS-A) Scores. 
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Pre-treatment (Bl) After 2-days (B2). After 9-days (B3) 
Placebo (Al) 76,40 (± 21,7) 
Clobazam (A2) 81.89 (± 21,1) 
Lorazepam (A3) 86,90 (±. 11,2) 
42 '65 (± 28' 5) 
54 '00 (±. 33 '7) 
41,13 (±. 27,8) 
27, 05 (±. 27' 9) 
27,04 (± 27 ,4) 
23 '04 (±. 19' 6) 
The means of the three treatment groups at .the t~re~ 
times of assessments for the Visual Analogue Scale for 
Anxiety are shown In Table 9 and illustrated in Fi~ure 5.-
The cell mean profile indicates. slightly different trends 
in anxiety scores in the three treatment groups during 
the course of treatment. The 2 way analysis of variante 
will indicate if these trends are significant. 
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TABLE 10: . Anova summary table for VAS-A. 
Source 
Between subjects 
A (Type of treatment) 
Subjects 
Within subjects 
B (Time of assessment) 
AB (Interaction) 
Residual 
** p < 0,01 
df 
2 
67 
2 
4 
134 
MS 
572,28 
1147,89 
55505,37 
66'V, 36 
376,13 
F ratio 
0,49 
147,57** 
1 '76 
Table 10 shows that the interaction (AB) effect is. in-
significant and therefore the main effects can be inter-
preted. The significant (p < 0,01) B main effect indicates 
that there was a general drop in VAS-A scores during treat-
ment. The lack of a sigriificant inter~ctton effect 
indicates that the drop in VAS-A was similar for all three 
treatment groups. A Tukey HSD analysi·s will reveal 
specifically how the overall B means differ. 
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TABLE 11: 
Bl (81,73) 
B2 (45,93) 
B3 (25 ,71) 
Tukey HSD results for overall B means, 
i.e. the overall average VAS-A mean scores 
of all three treatment groups combined are. 
·compared at the three times of assessment. 
I 
Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
15,40** 24, 17** 
8, 72** 
** p < 0,01 
Table 11 shows that the overall VAS-A means drop 
significantly (p < 0,01) from pre-treatment to the 
2-day assessment and continue to drop significantly 
(p < 0,~1) from the 2-day assessment to the 9-day 
assessment. The drop in VAS-A b~erall ave~~ge mean 
is also significant (p < 0,01) from.pre-treatment to 
the 9-day assessment. 
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6.1.3 Visual Analogue Scale for Motivation 
TABLE 12: Mean (±_ s.~.) Visual Analogue· Scale for 
Motivation (VAS-M) Scores. 
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Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
Placebo (Al) 61,0 (±_ 33,5) 
Clobazam (A2) 54,4 (±_ 34,0) 
Lorazepam (A3) 43,3 (±_ 34,7) 
70,6 (±_ 28,4) 
71,2 (±_ 28,4) 
50,3 (±_ 29,9) 
72,9 (±_ 27,2) 
72' 1 (±_ 32 '4) 
63 ~ 2 (±_ 26 '7) 
The means of the three treatment groups at the thr~e 
times of assessment for the Visual Analogue Scale for 
Motivation are shown in Table 12 and illustrated in 
Figure 6. The cell mean profile indicates essentially 
similar trends for the various treatment groups during 
the course of treatment. The 2 way analysis of var(ance 
will indicate what specific changes are significant. 
I 
'·; 79 
IS 
Al 
- A). 
I 
I "/ 
'S ~ I / I 
/ 
A\ / 
Ill 
VAS-M I fl.t,e..ho 
C Me.Ms) / 
/ 
SS" ~l. I 
C\c\..••Z"P\. 
Bl 82 . 83 
Pre-treatment After 2-days After 9-days 
FIGURE 6: VAS-M Cell Mean Profile. 
TABLE 13: Anova summary table for VAS-M 
Source 
Between subjects 
A (Type of treatment) 
Subjects 
Within subjects 
B (Time of assessment) 
AB (Interaction) 
Residual 
** p < 0'01 
df 
2 
67 
2 
4 
134 . 
MS 
5126,91 
1775,05 
4890,83 
330,94 
537,22 
F ratio 
2,89 
9, 1 O** 
0 '62 . 
Table 13 shows that he interaction (AB) effect is in-
significant and therefore the main effects can be inter-
preted. The significant (p < 0,01) B main effect indi-
cates that there was a general increase in VAS-M scores 
during treatment. The insignificant interactibn shows 
that this increase in VAS-M was similar for all three 
treatment groups. A Tukey HSD analysis will reveal 
specifically how the overall B means differ. 
80 
TABLE 14: Tukey HSD results for overall B means, 
i.e. the average VAS-M mean scores of 
all three treatment groups are compared 
at the three times of assessment. 
Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
Bl (52,88) 
B2 (64,08) 
B3 (69,41) 
* p < 0,05 
** p < 0 ,01 
4,04* 5,97** 
1,920 
Table 14 indicates that the overall VAS-M mean increases 
significantly (p < 0,05) from pre-treatment to the 9-day 
assessment. The increase from day-2 assessment to 
the day-9 assessment is not significant. The increase 
from the pre-treatment assessment to the assessment 
after 9-days is significant (p < 0,01). 
81 
6.1.4 Drowsiness Ratings 
TABLE 15: Mean (± s.d.) Drowsiness Rating Scores. 
Placebo (Al) 
Clobazam (A2) 
Lorazepam (A3) 
After 2-days (B2) 
0,40 (± 0,7) 
0,82 (± 0,8) 
1,26 (± 0,7) 
After 9-days (83) 
0,10 (± 0,4) 
0,55 (± 0,7) 
1,04 (± 0,8) 
Table 15 shows the mean drowsiness scores for th~ 
three treatment groups at the 2~day an~ 9-day assessments. 
There was no assessment of drowsin~ss level ~t pre-
treatment. The means are illustrated in figure 7 .. This 
cell mean profile indicates a general trend for the mean 
drowsiness to drop. The 2 way analysis of variance will 
indicate which changes are significant. 
82 
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FIGURE 7: Drowsiness Rating Cell Mean Profile. 
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TABLE 16: Anova summary table for Drowsiness Ratin~ 
Scores. 
Source 
Between subjects 
A (Type of treatment) 
Subjects 
Within subjects 
B (Time Of assessment) 
AB (Intera<:tion) 
Residual 
** p < 0 '0 l 
df 
2: 
6T' 
1 
.1 
67 
MS 
. 9 ,-36 -
0,76 
2,31 
0,02 
. 0 '29- -
F ratio 
12,27** 
7,88** 
0,07 
Table 16 shows that the interaction (AB) effect ·is in-
significant, -therefore the significa~t (p < O,OlJ A and B · 
. . 
main effects can be interpreted. The significant A mai~ 
/ 
effect indicates that the overall mean drowsiness ratings 
for the three treatment groups differ. A tukey HSO 
analysis will indicate which specific differences are 
significant. The significant B main effect' shows that the 
overall mean drowsiness at the -2-day assessment (the mean 
84 
of the three treatment groups is 0,82) is significantly higher 
than the overall mean drowsiness level at .the 9-day assessment. 
The overall mean at 9-days is 0,56. There is an overall 
s·ign-ificant dr·o.p in -drowsine.ss rating from the 2-day· assess-
ment to the 9-day assessment~ 
TABLE 17: Tukey HSD results for overall A means, i.e. 
the average drowsiness rating score~ for 
both times of assessment for each of the. 
three treatment groups. 
85 
Placebo (Al)· Clobazam (A2) Lorazepam (A3). 
Al (0,25). 
A2 (0,68) 
A3 (1,15) 
* p < 0 '05 
** p < 0,01 
3,38 
-
Table 17 indicates that the overall mean clobazam 
6,76** 
. 3' 77* 
drowsiness rating does not differ significantly from 
the placebo rating. The lorazepam rating is sigriificantly 
higher (p < 0,01) than the placebo rating and also signi-
ficantly higher (p < 0,05) than the clobaza~ rating. 
,·' 
6~1.5 Digit Symbol Substitution Test 
TABLE 18: 
Placebo (Al) 
Clobazam (A2) 
Lorazepam (A3) 
Mean (± s.d.) Digit Symbol Substitution Test 
(DSST} Scores. 
Mean Number completed in 90 seconds. 
Pre,..treatment (Bl) After 2,..days (82} After 9-days (83) 
23,8 (± 9,9) . 30,3 (+ 12,6) . 30,6 <± 15,l) 
24,9 (± 9,3) 31,0 (+ 11,3) 33,7 <± 12,7) 
21,7 (+ 8,3) 25, 1 (± a, 5 > · 29,0 (±. 10,6) 
'. . 
. , 
Table 18 shows the m~ans of the three treatment groups 
at the three times of assessment for the Oigit Symbol 
Substitution Test, these means are illustrated in .. 
Figure 8. A 2 way analysis of variance will show 
what specific ch~nges are significant. 
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TABLE 19: Anova summary table for DSST. 
Source df MS F· ratio 
Between subjects 
A (Type Of treatment) 2 "311, \ 1 , 1 1 
Subjects 67 '3 3 ~-<\-
Within subjects 
B (Time of assessment) 2 I os-2/\ 67,89**· 
AB (Interaction) 4 '11 s I l,77 
Residual 134 IS/; 
** p < 0,01 
,· 
The results in Table 19 indicate that the interaction 
(AB) effect is insignificant. This implies.that there 
is no difference in the trends between the three treatment 
groups and therefore overall means, i.e. the main effects 
. . . 
can be interpreted. The B.main effect is sig~ificant 
(p< 0,01). There is a general significant increase in 
DSST mean over the course of treatment. A Tukey HSD .. 
analysis will show which of the overall B means differ 
significantly. 
TABLE 20: Tukey HSD results for overall B means, 
i.e. the average DSST means f"or a 11 three 
' . 
treatment groups are compared. at the 
three times of assessment. 
89 
Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
Bl (23,47) 
B2 (28,80) 
B3 ( 31 ,08) 
** p <0,01 
11,32** 4 ,84** .. 
16' 16** 
The Tukey HSD analysis in Table 20 shows all the 
changes to be significant. The DSST overall means 
increase significantly from the pre-treatment assess-. 
men t to the as s es s men t after 2 -days and cont i n u·e to 
increase significantly to the 9-day assessment~ 
The increase from pre-treatment to the 9~day assessment .. 
is also therefore significant • 
. .. ···.;· 
6.1.6 Critical Flicker Fusion Threshhold 
' 
' 
TABLE 21: Mean (± s.d.) Critical Flicker Fusion 
Threshhold (CFFT). 
Mean number of cycles per second. 
90 
Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
Placebo (Al) 21,38 (± 2,6) 
Clobazam (A2) 21,20 (± 2,4) 
Lorazepam (A3) 21,42 (± 2,5) 
20,99 (± 2,5) 
21,16 (± 1,9) 
21,22 (± 2,4) 
21,23 (± 2,2) 
21,17 (± 0,2) 
20,75 (± 2,2) 
The means of the three treatment groups at the three 
times of assessment for the Critical Flicker Fusion 
Threshhold are shown in Table 21. Since all the means 
are very similar a cell mean profile would not serve to 
illustrate any trends and hence no graph has been drawn. 
A 2 way analysis of variance will reveal if there are 
any significant changes. 
. . 
TABLE 22: Anova summary table for CFFT scores. 
Source 
Between subjects 
A (Type of treatment) 
Subjects 
Within subjects 
B (Time of assessment) 
AB (Interaction) 
Residual 
df 
2 
67 
2 
4 
134 
MS · F ratio 
0;08 0,01 
13,6S 
1 '32 
1 ' 1. 5 
l, 12 
1 '18 
1 '02 . 
Table 22 shows that there are no significant changes in 
CFFT scores. 
91 
' .' 
·:. ' 
6.1.7 Inglis Paired-Associate Learning Test 
TABLE 23: Inglis Paired-Associate Learning Test (Inglis) 
Scores. 
Number of trials needed to attain three 
consecutive correct responses for each 
pair of words. 
92 
Pre-treatment (BI) After 2-days (B2) After 9-days (83) 
Placebo (Al) · 11,75 (! 7,3) 
Clobazam (A2) 11,93 (±_ 7,6) 
Lorazepam (A3) 13,43 (+ 11,8) 
8,3 (! 3,5) 
9,11 (! 6,0) 
10 (! IO, 7) 
9,9 (±. 4,9) 
8,52 (! 4,5) 
8 , 26 (! 6 '0 ) . 
The means of the three treatment groups at the three 
times of assessments for the Inglis Paired-Associate 
Learning Test are shown in Table 23 and illustrated 1n 
Figure 9. The scores show a tendency to decrease. 
and the 2 way analysis will reveal what changes are 
significant. 
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. TABLE 24: Anova summary table for Inglis scores. 
Source 
Between subjects 
A (Type of treatment) 
Subjects 
Within subjects 
B. (Time of assessment) 
AB (Interaction) 
Residual 
** p < 0, 01 
2 
67 
2 
4 
134 
MS 
9,93 
124,51 
259,78 
22, 13 
20, 16 
F ratio 
0,08 
12,89** 
1 , 1 0 
Table 24 shows that the interaction effects are in-
significant. Therefore the main effects can be inter-
preted •. The B main effect is significant (p < 0,01). 
This indicates that there is significant change in the 
overall B means (time of assessment). The overall 
me a n a t a p a rt i c u 1 a r t i me of a s s e s s men t d i ffe1r s f r om 
other overall means at a particular time df assessment 
and a Tukey HSD analysis which shows which specific overall 
B means differ. 
94 
TABLE 25: 
Bl (12,37) 
82 (9' 14) 
B3 (8,93) 
Tukey HSD results for overall B means,· 
I 
i.e. the overall average Inglis mean· 
scores of all three treatment groups 
are compared at the three times of ~~: 
assessment. 
Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
6,02** . 6 ;41 **: 
0,38 .. 
** p < 0,01 
Table 25 indicates that the overall mean (82) of · 
lnglis scores at 2 days is significantly (p < 0,01) · 
lower than the mean at pre-treatment (Bl).· The 
overall-Inglis means at B2 and B3 do not differ 
significantly. The reduction in overall Inglis· 
mean from pre-treatment (Bl) to the assessment at 
9-days (83) is significant (p < 0,01) • 
. . : 
"' .. ·~ ... . . · .... . .... :· · ... 
-:·.: ...... . .. ':. :. : . · ........ -~ . : .:·.: 
95 
6.1.8 Purdue Pegboard Test - Preferred Hand Task 
TABLE 26: Mean (± s.d.) Purdue Pegboard Test (PPT)-
Preferred Hand Scores. 
96 
Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
Placebo (Al) 13, l (± l,8) 
Clobazam (A2) 13,3 (± 1,9) 
Lorazepam (A3) 13,5 (± 2,0) 
14,6 (± 1,7) 
14,2 (± 1,8) 
13,6(±1,7) 
15, l (± l, 9) 
_14,l (± 1,8) 
14 ,6 (± l ,6) 
The means of the three treatment groups at the three 
times of assessment for the Purdue Pegboard Test -
Preferred Hand task are shown in Table 26 and illus-
trated in Figure 10. The cell mean profile shows that 
t~ere is an improvement in performance. The 2 way 
analysis of variance will reveal if there are any 
significant improvements. 
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· TABLE 27: Anova summary table for PPT ~ Preferred 
Hand scores. 
Source 
Between subjects 
A (Type of treatment) 
Subjects 
Within subjects 
B (Time of assessment) 
AB· (Interaction) 
Residual 
** p< 0,01 
df 
2 
67 
2 
4 
134 
MS 
2,81 
7,62 
29,95 
4,72 
1 ' 1 4 
F ratio 
0,37 
26,33** 
4' 15** 
The 2 way anolysis of variance (Table 27) shows that 
the interaction (AB) effect is significant (pc( 0,01). 
This means that the main effects cannot be interpreted 
and an analysis of the simple main effects is required 
to ascertain the specific significant changes. 
98 
TABLE 28: 
Source 
A at Bl 
A at 82 
A at 83 
Within 
B at Al 
B at A2 
B at A3 
Residual 
Simple main effects summary table for 
PPT - P~eferred Hand scores. 
df' _MS 
2 0 '98 -
2 5,41 
2 5,58 
201 3,30 
2 21 '6 7 
.2 6,33 
2 9' 10 
134 1 '13 -
** p < 0,01 
99 
F ratio 
0,29 
1 -64 -
- ' 
1,69 
/ 
19,04** 
5,57** 
7 99** 
- ' 
The simple main effects analysis {Table 28) reveals three 
significant (p < 0,01) results. The mean placebo (scores) 
differ from each other at one or more of the times of 
assessment (8 at Al). This also applies to the clobazam 
group (8 at A2) and to the lorazepam group (8 at A3). 
A Tukey HSD analysis will reveal which specifi~ cell 
means differ significantly. 
TABLE 29: Tukey HSD results for Bat Al, i.e. 
mean PPT-Preferred Hand scores for 
placebo group at the three times of 
assessment. 
100 
Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
Bl (13,05) 
B2 (14 ,55) 
B3 (15,05) 
** p < 0,01 
6,69** 8,38** 
2' 10 
The analysis (Table 29) shows that the pre-treatment 
mean (Bl) is significantly (p < 0,01) lower than the 
mean at the 2-day assessment (B2) and the mean at 
the 9-day assessment (B3). The means at the 2-day· 
assessment and the 9-day assessment do not differ 
significantly. 
TABLE 30: HSD results for Bat A2, i.e. meanoPPT-
Preferred Hand scores for clo~azam group 
at the three times of assessment. 
101 
Pr~-treatment (Bl) After 2-days (B2) . After 9-days (B3) 
Bl (13 ,30) 
B2 (14' 19) 
B3 ( 14 ,07) 
4,33** 3 '79'!f-~-; 
0,54 .· 
* p < 0,05 
** p < 0 ,01 
The analysis (Table 30) indicates that there is a 
significant (p < 0,01) improvement ·iri performance· 
•. 
from pre-treatment (Bl) to the 2-day assessment (B2). ·· 
The mean at the 2-day assessment (82) does not differ 
from the mean at the 9-day assessmerit (83}~ The mean · 
at the 9-day assessment is significantly (p <. 0,05) 
greater than the pre-treatment (Bl) mean.,_ 
.·· ·. 
TABLE 31: HSD results for Bat A3, i.e. mean _ 
PPT-Preferred Hand scores for loraze-
pam group at the three times of assessment. 
102 
Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
Bl ( 13 ,48) 
B2 (13 ,57) 
B3 (14 ,61) 
** p < 0,01 
0,39 5,09** 
4,69** 
The analysis (Table 31) shows that the mean score at 
pre-treatment (Bl) does not differ significantly from 
the mean score at 2-days (B2). The mean~ at 9-days 
is significantly higher (p < 0,01) than the mean at 
2-days and the pre-treatment mean. 
6.1.9 Purdue Pegboard Test - Both Hands Task 
TABLE 32: Mean (±_ s.d.) Purdue Pegboard Test (PPT) -
Both Hands Scores. 
Mean number completed in 30 seconds~ 
103 
Pre-treatment (Bl) After 2-days (82) After 9-days (B3) 
Placebo (Al) 10,2 (±_ 1,3) 
Clobazam (A2) 9,9 (±_ 1,4) 
Lorazepam (A3) 9,7 (±_ 1,4) 
10,5 (+ 1,2) 
10, 2 (±. 1 , 8) 
10,0 (±. 2,0) 
11 , 2 (±_ 1 , 5) 
10,5 (±_l,6} 
10, 2 (±. · 1, 6) 
Table 32 shows the means of the three treatment groups 
. at the three times of assessment for the Purdue Peg-
board Test (PPT) - Both Hands - Section. The means are 
illustrated in Figure 11. There is a tendency for 
performance to improve and the 2 way analysi~ of 
variance will show which changes are significant. 
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TABLE 33: Anova summary table for PPT - Both Hands 
scores. 
105 
Source df MS F ratio 
Between subjects 
A (Type of treatment) 
Subjects 
Within subjects 
B (Time of assessment) 
AB (Interaction) 
Residual 
** p < 0,01 
2 
67 
2 
4 
134 
7,46 
5,97 
8,80 
0,37 
. 0, 68. 
Table 33 shows that the interaction effect is not 
significant and therefore the significant (p..( 0,01) 
B main effect can be interpreted. The significant 
1,25 
12,91** 
0,55 
B main effect indicates that the overall average PPT - Both 
Hands means at the various times of assessment differ from 
one another. A Tukey HSD analysis will show which 
differences are significant. 
··. 
J. 06 
TABLE 34: Tukey HSD results for overall B means, 
. . 
i.e. the overall average PPT - B6th 
Hands scores of all three treatment groups 
are compared at the three times of assessment • 
. 
Pre-treatment (Bl) After 2-days (B2). After 9-days (B3) 
Bl (9,91) 
B2 (IO ,23) 
B3 (IO ,63) 
* p < 0,05 
** p < 0,01 
3, 17. 7,22** 
4,05* 
Table 34 indicates that the overall PPT - Both Hands 
mean at pre-treatment (Bl) does not differ significantly 
from the overall mean at 2-days (B2) but doe~ differ~. · 
significantly (p < 0,01) from the overall mean at 9-days 
which is significantly greater. The overall mean at 
83 is also significantly greater (p < 0,05) .than ,the 
overall mean at B2. 
6.1.10 Purdue Pegboard Test - Assembly Task 
TABLE·35: Mean (± s.d.} Purdue Pegboard Test (pPT) -
Assembly Scores. 
Mean number completed in 90 seconds. ' 
1. 0 7 
Pre-treatment (Bl) · After 2-days (82) After 9-days (B3) 
Placebo (Al) 43,5 (± 8,0) 
Clobazam (A2) 42,l (± 7,9) 
Lorazepam (A3) 40,7 (± 7,4) 
47,0 (± 8,9) 
46,5 (± 6,2) 
41,3 (± 8,0) 
48,3 (± 6,8) 
46,0 (± 7,8) 
46 ,0 (± 9 ,4) 
The means of the three treatment groups at the.three· 
times of assessment for the PPT - Assembly task are 
shown in Table 35 and illustrated in Figure 12. The 
cell mean profile indicates a tendency for performance 
to improve with slightly different trends for the three 
treatment groups. A 2 way analysis of variance will 
reveal which changes are significant. 
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TABLE 36: Anova summary table for PPt - Assembly 
scores 
Source 
Between subjects 
A (Type of treatment) 
Subjects 
Within subjects 
B (Time of assessment) 
AB (Interaction) 
Residual 
* p<0,05 
** p < 0'01 
df 
2 
67 
2 
4 
134 
MS 
227,01 
150,90 
376,75 
43,49 
16,54 
109 
F ratio 
1 '50 
22,78** 
2,63* 
The 2 ~ay analysis variance (Table 36) shows that the 
interaction (AB) effect is significant (p < 0,05). 
This means that the main effects cannot be interpreted 
and an analysis of the simple main effects is ~equired 
to ascertain the specific significant trends.· 
TABLE 37: Simple main effects summary table for 
PPT - Assembly scores. 
1. 10 
Source df MS F ratio 
A at Bl 
A at B2 
A at B3 
Within 
B at Al 
B at A2 
B at A3 
Residual 
* p < 0. 05 
** p < 0,01 
2 81. 02 l,32 
2 224,98 3,67* 
2 37,82 0,62 
201 61,32 
2· 121,25 7,33** 
2 140,53 8,51** 
2 195,78 11,84** 
134 16,54 
The s i mp 1 e ma i n effects an a 1 y s i s ( Tab 1 e 37 ) rev ea 1 s th re e .. 
significant (p < 0,01) results and one significant (p < 0,05) 
result. The mean placebo scores differ from each other at 
one or more of the times of assessment (Bat Al). This 
also applies to the clobazam group (B at A2) and to the· 
lorazepam group (Bat A3). In addition, the three. 
treatment groups differ significantly (p < 0,05) at th~. 
2-day assessment (A at B2). A Tukey HSD an~lysis will 
show which specific cell means differ significantly . 
. ·: ~ · .. ' 
TABLE 38: Tukey HSD results for A at 82, i.e. 
mean PPT-Assembly scores for the three 
treatment groups at the assessment 
after 2-days. 
111 
Placebo (Al) Clobazam (A2) Loraz~pam (A3) 
Al (47,05) 0,67 6,49** 
A2 (46,48) 6,29** 
A3 (41,35) 
The analysis (Table 38) shows that the clobaza~ and 
placebo means do not differ significantly. The lorazepam 
is significantly (p < 0,01) less than the clobazam mean 
and the placebo mean. 
TABLE 39: Tu key HSD resu 1 ts for B at' Al, i.e. 
mean PPT - Assembly scores for placebo 
group at the three times of assessme~t. 
112 
Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
Bl (43,55) 
B2 (47,05) 
B3 (48,3) 
* p < 0,05 
** p < 0,01 
3,85* 5 22** 
' 
1,37 
The analysis (Table 39) shows that the mean at .the, 
2-day assessment is significantly (p < 0,05) greater 
than the mean at 9-days. The mean at 9-days is 
., 
significantly (p < 0,01) greater than the pre~treatment 
mean. The means at 2-days and at the 9-day assessment 
do not differ significantly. 
TABLE 40: Tukey HSD results for Bat A2 i.e. 
mean PPT ~ Assembly scores. for the 
clobazam group at the three times of 
assessment. 
113 
Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
Bl (42,15) 
B2 (46,48) 
B3 (45,96) 
** p < 0,01 
5,53** 4,87** 
0,67 . 
The analysis (Table 40) shows that the mean at the 
2-day assessment is significantly (p < 0,01) greater 
than the mean at pre-treatment. The mean ai 9-days 
is significantly (p < 0,01) greater than the mean at 
pre-treatment. The mean at 9-days does not differ 
from the mean at the 2-~ay assessment. 
TABLE 41: Tukey HSD .results for Bat A3 i.e •. 
mean PPT - Assembly scores for the 
lorazepam group at the three times of'· 
assessment. 
1.14 
Pre-treatment (Bl) After 2-days (B2) After 9-days (B3) 
Bl ( 40, 70) 
B2 {41,35) 
B3 (46,04) 
** p < 0 ,01 
0,77 6,31** 
5,54** 
The analysis (Table 41) indicates that the mea~·at the 
2-day assessment does not differ from the· mean at 
pre-treatment. The mean after 9-days is significantly 
(p < 0,01) greater than the mean after 2-days and the 
pre-treatment mean. 
... 
6.1.11 Choice Reaction Time 
TABLE 42: Mean (! s.d.) Choice Reaction Time (CRT) 
Scores. 
Mean number of seconds taken to react. 
115 
Pre-treatment (Bl) After 2-days (B2) After 9-days (83) 
Placebo (Al) 0,657 (! 0,07) 
Clobazam (A2) 0,666 (! 0,08) 
Lorazepam (A3) 0,674 (± 0,07) 
0,629 (+ 0,07) 
0,643 (! 0,06) 
0,663. (± 0,06) 
0 ' 5 94 C:t. 0 ' 06 ) 
0,625 (± 0,08) 
0,621 (± 0,06) 
The means of the three treatment groups at the three 
times of assessments for the choice reaction time 
test are shown in Table 42 and illustrated .in Figure 13. 
The cell mean profile indicates that there is a tende~cy 
for the CRT times to improve. A 2 way analysis of 
variance will reveal any significant changes. 
0,, 
I 
j 
! 
r 
' !
I 
0 (.S° t 
I ' 
0 bl 
I 
S7 o, 
I 
I 
L.:..·i:i."E.~P"'"" 
Al 
Al"-.. (.. '.:.i.:.~ .. 2.c:( II'\ ......... 
f\ I 
Bl 
.......... 
Pre-treatment 
FIGURE 13: 
'. ' 
116 
Ai 
82 83 . 
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CRT Cell Mean Profile. 
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TABLE 43: Anova summary table for CRT scores. 
Source 
Between subjects 
A (Type of treatment) 
Subjects 
Within subjects 
B (Time of assessment) 
AB (Interaction) 
Residual 
** p< 0,01 
df 
2-
67 
2 
4 
134 
· MS 
0,012 
0,01 
0,048 
0,001 
0,0014 
F ratio 
1 '02 
34,43** 
1,02 
Table 43 indicates that the interaction effect is not 
. significant and therefore the significant (p < 0,01) 
B main effect can be interpreted. This- significant B 
' . 
main effect implies that the overall average CRT at the 
various times of assessments differ and a Tukey HSD will 
reveal the specific significant differences.· 
TABLE 44: Tukey HSD res~lts for bverall B m~ans, 
i.e. the overall average CRT mean scores 
for all three treatment groups combined 
are compared at the three times of 
assessment. 
118 
Pre-treatment (Bl) After 2-days (B2). After 9-days (B3) 
Bl (0,666) 
B2 (0,645) 
B3 {0,619) 
** p < 0,01 
4,70** 10',47** 
5, 77** 
Table 44 reveals that all the means differ significantly 
(p < 0,01) from each other. There is an improvement 
from pre-treatment to the 2-day assessment and to the 
9-day assessment in CRT. 
:, '; 
6.2 HOMOGENEITY OF ERROR VARIANCE 
All the Fmax ratios were insignificant and therefore 
there is homogeneity of variance for all the two-way 
anovas. 
6.3 CHI-SQUARE ANALYSIS OF PATIENTS WHO COMPLETED AND 
COMPLIED WITH TREATMENT. 
The chi-square (X 2 = 1,057) is insignificant, thus the 
number of patients in each treatment group does not 
differ significantly (20 in placebo group, 27 in clobazam 
group and 23 in lorazepam group). 
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The results of the correlation matrices (tables 45 to· 53) 
'· 
will be considered in terms of trends· that emerg~ ih th~ 
, ..
relationship between ~ertain variable~. The relation~hip that 
"'· 
will be considered are those that are of a practicaVand/or 
theoretical interest·. lhe following relationships will be 
considered:-
(a) ·The relationship between HAS and VAS-A scores (i.e. the · 
two measures of anxiety). 
(b) The relation between HAS and VAS-M scores and b~tween 
VAS-A and VAS-M scores (i.e. the me~sures of anxiety 
and the VAS measure of motivation). 
(c) The relationship between the various· performance'.measures 
- DSST, the three pegboard tests, CRT .and Inglis tests. 
(CFFT is considered later). 
" 
(d) The relationship between the measures of anxiety and the 
performance variables. 
( e) The relationship between the drowsiness ratina'arid the 
- •· ~ 
various performance measures, and the relationship between 
the drowsiness rating and the anxiety ~nd VAS-M variables. 
(f) The relation between CFFT and the other variables. 
(a) The relationship betweeri HAS and VAS-A scores 
The correlation coefficient (Pearson produc~-m~ment) 
between these two measure is' significant in seven ,out 
' ' " 
. ' . . . ! 
of a possible nine instances. ' The correlations 
. '· . 
'· 
are positive and high. There is thus a strong trend 
for scores on the HAS to be equivalent. in magnitude 
to s c o re~ on the VAS - A . F o r e x amp 1 e · a pa t i e n t · w i th 
a high anxiety score on the HAS is likely to hav~ 
a high anxiety score on the VAS=A. 
{b) The relationship between the measures of anxiety 
and the VAS-M scores 
The correlation coefficient between HAS and VAS-M 
is significant and negative in two out of a possible 
nine instances. The correlation coefficient between 
VAS-A ~nd VAS-M is significant and negative in only 
one instance out of a possible nine instances. There 
is thus a trend for scores on the anxiety m~a~u~es to 
be related to score on the VAS-M. The ~orrelation 
is negati¥e and hence.patients who have a high VAS-M 
score will have low anxiety scores. Since only' three 
out of 18 correlationsaresignificant this trend is not 
very strong. 
(c) The relationship between the various performance 
variables 
The correlations between the DSST, the three pegboard 
tests, CRT test and the Inglis test are significant in 
4 6 ·· out of a poss i bl e 1 4 4 o cc as ions . In so me case s 
th e co r re l a t i on~ a re n e g a t i v e i n o th e rs p o s i t iv e b u t i n 
1.30. 
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all of the~e 46 instances the correl~tio~ indicate 
that a patient who performs well on one· of these tests has 
good performance on the other tests (alternatively 
bad performance on one of these tests is likely to go 
with bad performance on the other tests). There is 
thus a fairly strong trend for performance on the 
various measures to be related. 
(d) The relationship between the measures of anxiety 
and the performance measures 
There are 18 significant correlations (out ~fa 
possible 108 instances) between either HAS or VAS-A 
and the various performance measures •. The correlatibn 
are either positive or negative but in all'l8 instances 
they show an inverse ~elationship between anxiety and 
performance. Specifically this means that· higher 
anxiety is associated with poor performance or al-
ternatively low anxiety is associated with good , 
performance. Since 18 correlations out of 108 are 
significant the trend is not very strong. 
(e) The relationship between the drbwsiness rating and 
the other variable 
There are four significant correlations between .drowsiness 
and performante for the clobozam group at the 2-day 
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assessment and one significant correlation between 
drowsiness and a performance variable (CRT) for the 
clobozam group at the 9-day assessment. No other 
correlations between the drowsiness rating and 
performance are significant. There are thus five 
instances of significant correlations .between· 
drowsiness rating and the performance variables out 
of a possible 36 instances. The significant correlation 
show drowsiness rating to be inversely related to 
perf.ormance (higher drowsiness associated with poorer 
performance). This trend only occursin the clobozam 
group and not in the placebo or lorazepam group. The 
trend in the clobazam group is fairly strong (five out 
of 12 instances). 
In two instances the correlation between drowsiness 
rating and the VAS-A is significant. The occurs in the 
clobQzam group at the two and nine day assessments. 
The correlations are positive ind.icating that higher 
drowsiness rating are associated with higher VAS-A 
scores. These are the only instances of significant 
correlation between drowsiness rating and the VAS-A or 
HAS or VAS-M score. There are thus only two significant 
correlations out of a possible 18 instances. The trend 
for drowsiness to be related to be anxiety measures or 
the VAS-M measure is therefore minimal.· 
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The relationship between the CFFT and the other variables 
There are only three significant correlation between 
CFFT and the other variables. The correlatioh bet~e~n 
VAS-A and CFFT is· significant.in the lorazepam group at 
the 2-day assessment. The correlations is negative 
indicating an inverse relationship between VAS-A score and 
'l. CFFT. This implies that higher anxiety score.is associated 
" 
with lower CFFT and vice versa .. Since there is only one 
instance of a significant correlation between the ·anxiety 
measures and CFFT out of a possible 18 instances the. 
trend :is .very minimal. 
There are no instances of significant correlations 
between CFFT and the VAS-Mor the drowsiness ratings. 
'.The other two significant correlations are.between 
CFFT. and two perf6rmance variables:· There is a 
significant positive correlation between CFFT and PPT-B 
in the clobozam group at the pre-treatment assessment 
and between CFFT and DSST in the clobozam group at the 
9-day assessment. This is also a minimal trend as 
there are only two significant correlations out o~;a 
' possible 45 instances. The direction of the correlatio~ 
indicate that higher CFFT is associated with good per-
formance and alternatively low CFFT is: associated with 
poor performance. 
i •. 
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7. DISCUSSION 
The non-adherence rate of 41,67 percent compares.favourably 
to the rate found in out-patients. Blackwell (1976) writes 
that non-adherence is reported in between. 25 and 50 Percent 
of outpatients. The slight differences in the final total 
of patients who completed and complied with treatment in 
each treatment group are not significantly different from 
what would be expected by chance. This study is interested 
in the effects of the drugs on anxiety and performance on 
those patient who attually complete and comply ~ith treatment 
and hence there is no reason in this case to consider the 
non~adherent patients. 
Most of the patients who successfully completed. the trial. 
and complied with treatment wer~ females (92,5 percent). 
The predominance of female patients is representative of 
the actual proportion of benzodiazepine users (approxi~ate 
70 percent females) (Bellantuono et al., .1980). As dis-
cussed in the introduction (Section 2.4.2) many studies 
assessing the psychomotor effects of the benzodiazepines have 
utilized male subjects. The median educational level of 
the patiehts (Standard Five) is relatively low and· the 
implications of this will be discussed at a later stage 
when the generalisability of the findings aie considered. 
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The results of the Hamilton Anxiety Scale (HAS) show that 
there is an initial significant improvP.mPnt in anxiety at 
2 days in all three treatment groups. A further improve-
ment at 9 days was evident only in the benzodiazepine 
groups. This indicated an initial placebo effect which 
was not enhanced with time. Thus from the standpoint of 
anxiolytic efficacy clobazam and lorazepam were superior to 
placebo. Bellantuono et al. (1980) who reviewed the 
studies that have assessed the anxiolytic efficacy of the 
benzodiazepines reported that out of a total of 85 studies, 
44 results showed the drug to be much better than the 
placebo, 26 showed the drug to be slightly better than 
the placebo, 14 showed no difference and one study showed 
the drug to be worse than the placebo. The results of 
this study can be classed as showing that clobazam and 
lorazepam are slightly better than placebo. Substantial 
placebo effects are generally found witb anxious patients 
(Greenblatt and Shader, 1974). In addition, even greater 
placebo effects have been found in previous studies that 
have involved patients of a relatively low educational 
level (Rickels et al., 1970; Hesbacher et al., 1970). 
Another significant result that emerged for the HAS mean 
scores is the initial significant difference between the. 
placebo group and the drug groups. The placebo group 
pre-treatment HAS score is significantly lower than both 
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the clobazam and the lorazepam group. The actual difference 
in mean scores is not very large .. The initial mean placebo 
score (20,65) is only just over 2 digits lower than the 
initial clobazam score (22,74) and just o~er 3 digits lower 
than the initial lorazepam score (23,91). It is unlikely 
that such small initial differences will have any important 
influences on either the anxiety changes or the performance 
changes observed in the study. Since the patients are 
randomly assigned to the three treatment groups, this 
initial difference arose entirely by chance. If the 
initial placebo group mean score had been lower (say 15), 
then this far lower initial anxiety level.could have had 
considerable influence on anxiety and performance changes 
over the course of treatment. Anxiety changes in the 
placebo group would probably be far less because of the 
/ 
initial lower ~nxiety and psychomotor performance would pro-
bably be initially at a higher level of. the lower anxiety 
state of the placebo group. Since .the placebo group is 
used as a comparison group in the interpretation of anxiety 
and performance changes in the drug groups, a large initial 
difference in placebo and drug group anxiety· levels ~ould 
have made interpretation of the results far more complicated 
than if no difference or relatively small differences are 
found. Luckily the initial differences found in this 
study, although significant, are relatively small; 
This small difference in anxiety score does not seem to 
have had any important influence over the initial psycho-
motor performance level. If there had been a majdr 
' I 
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influence one would predict a higher initial performance 
level in the placebo group as of the lower initial anxiety 
level. ·This is not found. There are no significant 
differences in the initial psychomotor performance level 
in any of the psychomotor tests. The placebo group's 
initial performance ranks first on two of the performance 
tests, second on two of the performance tests and third 
on the remaining three performance tests. Hence the 
initial small difference in placebo anxiety level from the 
drug groups has not had any influence on initial performance 
level and can therefore be ignored when the performance 
changes are interpreted. Similarly the ~nitial lower 
anxiety mean score has not greatly influenced the anxiety 
changes in the placebo group. If there had been a major 
influence one would have expected far less initial change 
in the placebo.group than the large change observed in 
anxiety level from pre-treatment to the 2-day assessment. 
The initial lower placebo HAS mean score has. also been 
ignored when the anxiety changes have been interpreted. 
The results of the.visual analogue scale-anxiety (VAS-A) 
scores showed a general tendency similar in all three 
treatment groups for anxiety level to decrease. The 
decrease from pre-treatment (overall average mean of 81,73) 
f to.the 2-day assessment (overall average ·mean of 45,93) was l . 
greater (a diffetence of 35,8) than the drop from the 2-
day assessment to the 9 day assessment (overall average 
mean of 25,71). The latter difference is 20,22. Both 
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decreases were significant (p <0,01). As previously 
discussed, for the HAS there were different trends· for 
each of the treatment groups. The drug groups show~d~ 
a continual significant decrease but the placebo group 
' 
showed an initial significant decrease followed by a level-
ling off. Therefore, a fairly similar result is found for 
the VAS-A scale except that the placebo group does not show 
the levelling off of anxiety level to the same extent as 
shown by HAS measurements. In actual fa~t, the change in 
VAS-A mean score from day-2 to day-9 is lowest in.the 
placebo group, but the change is not small enough to result 
in a significant interaction effect such as the one found 
for the HAS •. The correlation coefficients between VAS-A 
scores and HAS scores also show that there is a strong 
trend for scores on tne VAS-A to be equivalent in magnitude 
to scores on the HAS. 
The visual analogue scale-motivation (VAS-M) scores do not 
show different trends for the three treatment groups.· 
There is an overall tendency for motivation level to 
increase from pre-treatment to the 2-day assessment. The 
increase from the 2-day assessment to the 9 day assessment 
is far less and insignificant. The overall change from 
pre-treatment to the 9-day assessment is also significant. 
The changes in motivational levels (assessed by.the VAS-M) 
found are probably directly related to the general improvement 
felt by the patients brought about by a lowerin~ of anxiety 
level. The correlation coefficients between VAS-M·and 
the anxiety measures do in fact show a ~light trend (3 
significant correlations out of a possible 18 instances) 
for improved motivation to1 be associated with decreased 
anxiety. The rudimentary assessment of motivational level 
was included to assess if clobazam treaiment re~ulted in 
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motivational enhancement. Since there was no difference in 
the extent of improvement of motivation in· the three treatment 
groups this assessment does not indicate that clobazam is 
in any way resulting in motivational enhancement over and 
above that found in the placebo and lorazepam group. 
The overall drowsiness rating of the lorazepam group is 
significantly greater than both the clobazam group and the 
placebo group. The clobazam and placebo groups do not 
differ in overall drowsiness rating. There· is also a sig-
nificant decrease in overall drowsiness rating from the day-
2 assessment to the 9-day assessment. These. results indi-
cate. a greater subjective sedative effect in the lor~zepam 
group as compared to the clobazam and placebo group. The 
extent of drowsiness decreased as tre~tment pr6gressed in 
all three treatment groups. In the introduction it was 
pointed out that the average incidence of drowsiness in 
clinical trials with clobazam is about 17 percent in those 
patients treated with clobazam relative .. to about 6 percent 
for those patients receiving a placebo. In double-blind 
studies comparing clobazam with diazepam the overall inci-
dence of reported drowsiness is very slightly less for 
clobazam. A detailed examination of the incidence of 
,· ' 
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drowsiness in the three treatment groups reveals that for 
the placebo group at the 2-day assessment the incidence of 
reported drowsiness is 35 percent made up ·of 20 percent mild 
drowsiness (rating of 1) and 15 percent moderate dr6wsiness 
(rating of 2). In the clobazam group at the 2-day 
assessment the incidence of reported drowsiness is 55,5% 
made up of 29,6% mild drowsiness and 25,9% moderate drowsiness. 
In the lorazepam group.the reported incidence at 2 days is 
87% made up of 47,8% mild and 39,1% moderate drowsiness. 
At 9 days the incidence in the placebo group is ~% (1 patient 
reported moderate drowsiness), in the _clobazam group 40,7% 
(25,9% mild and 14,8% moderate) and in lorazepam 69,6% 
(34,8% mild and 34,8% moderate). 
The incidence of moderate drowsiness assessed at 9-days for 
the placebo group (5%) and the clobazam group (14,8%) are 
very similar to the average figures tound in tlinical trials 
for clobazam (17%) and placebo (6%). It is faifly likely 
that drowsiness is usually assessed after about one week 
of treatment and that often at least moderate drowsiness 
needs to be reported by a patient for it to be noted by an 
investigator as an incidence of drowsiness. This study 
shows the need to include a shorter term eva·1uation of 
drowsiness. In addition, it is necessary to gain a more 
detailed assessment of drowsiness by ascertaining the degree 
of drowsiness experienced by a particular patient instead 
of simply noting the incidence of drowsiness. The latter 
approach is generally applied in clinical trials. 
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The lack of pre-treatment assessment of drowsiness rating 
is similar to the standard adopted in clinical trials of 
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assessing side-effects once treatment has commenced. This 
assumes an initial equivalent minimal drowsiness level in all 
three treatment groups. This is probably correct but not 
necessarily so. Thus a slight criticism of the approach 
used in this study and in other clinical trials is the 
lack of pre-treatment assessment of drowsiness. Using a 
pre-treatment assessment would have been more thorough 
although probably unnecessary. Further aspects of the 
findings on the degree of drowsiness will be dealt with 
in a·-1ater part of the discussion. 
The digit symbol substitution test (DSST) mean scores show 
similar trends in all three treatment groups. Performance 
improves significantly from pre-treatment to the 2-day 
assessment and continues to improve significantly to ·the 
9~day assessment. The overall change from pre-treatment 
to the 9-day assessment is thus also a significant improve-
'llent. The general overall improved performance can be 
\ ,' \ ·. · )\ c.counted for by a I earning effect and a I so Prob ab Iy by a 
\ \, ";::~::i:: s:n 0 ::::::: ::·::;rov:::::n~ n a::S:i :::::::::ce in 
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their patient study and they attributed thi~ to a learning 
effect. As discussed in the introduction, it is also 
very likely that a reduction in anxiety will result in 
improved performance. When the effects of the 1,4 benzodiaze-· 
pines (including lorazepam) on psychomotor performance were 
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considered in the introduction (Section 3.1), it was noted 
that the DSST was sensitive in detecting impaired performance 
in non-anxious volunteer subjects. Thus on the basis of 
volunteer studies one would have expected impaired perform-
ance in the lorazepam group. This is not found, the 
lorazepam group shows a similar trend to that found in the 
placebo and clobazam group, of improved performance. This 
finding will be considered again later in the discussion, 
but at this point it should also be noted that as indicated 
in the introduction, research shows that patients have 
significant impairment on fewer occasions than volunteers 
on a specific test such as the DSST. The clobazam group 
also shows improved performance and this lack of any indica-
tion of impaired performance is similar to that found in 
volunteer studies with clobazam. 
The critical flicker fusion threshhold (CFFT) results show 
that there are no significant changes in any of the drug 
groups. This lack of change is what one would expect 
in the placebo group. Volunteer arid patient studies with 
clobazam have indicated that clobazam either does not 
affect CFFT or results in significantly elevated CFFTs. 
Therefore the lack of change found in the clobazam group 
confirms the previously findings with clobazam. Volunteer 
studies with lorazepam have shown that a consistent and 
significant reduction in CFFT. Hente on the basis of 
these studies one would have expected a reduction in CFFT 
in the lorazepam group. This reduction is not found in 
this study. Th i s f i n d i n g w .i 1 1 be con s i de red a g a i n i n a 
later part of this discussion. 
The Inglis paired-associate learning test mean scores show 
similar trends in all three treatment groups •. There is 
an initial significant improvement in performance from 
pre-treatment to the 2-day assessment followed by a lack of 
improvement in performance from the 2-day to the 9-day 
assessment. The overall improvement in performance from 
pre-treatment to 9-days is significant. The general 
improvement in performance in all three treatment groups 
can be explained by a learning effect and an improvement 
in performa·nce due to a lowering of anxiety. Th?lack of 
general improvement from. 2-day assessment to the 9-day 
assessment indicates that for the Inglis test performance 
had improved critically to a _peak level and would not 
improve beyond thi~ even though the patients' anxiety was 
generally reduced. This shows a different learning curve 
to what was found for the DSST. 
On the basis of previous studies on volunteers one would 
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have expected that the lorazepam group would show impairment on 
this memory test. Once again this study shows that the 
expected impairment is not found in patients. The clobazam 
group shows no impairment on this memory test and this is 
what one would predict on the basis of volunteer studies. 
··, 
The Purdue pegboard test-preferred hand task (PPT-P) mean 
scores show different trends in performance improvement 
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over time in the three treatment groups. This is the first 
psychomotor performance m~asure to show different trends 
in the three treatment groups. In the placebo group there 
is an initial significant i~provement in ~erformance from 
pre-treatment to the 2~day assessment. Performince continues 
to improve slightly but the change from the 2-day to the 
9-day assessment is insignificant. The overall change 
from pre-treatment to the 9~day assessment is also 
significant. The improved .Performance in the placebo 
group can be attributed to a learning effect and to the 
reduction of anxiety resulting in improved performance. 
In the clobazam group there is a similar initial significant 
improvement in PPT-P performance from the pre-treatment 
assessment to the 2-day assessment. Performance at the 9-day 
! ,, 
assessment is at a slightly lower level than performance 
at the 2-day assessment but this change is insignificant. 
The overall change from pre-treatment to the 9-day assessment 
is also significant. Thus the clobazam group shows a 
similar trend (of initial improved performance followed by 
a levelling off) as that found in the placebo group. 
On the other hand, the lorazepam group shows a different 
trend to that found in the place~o and clobazam groups. 
There is no initial significant improvement from pre-treatment 
to the 2-day assessment. There is a significant improvement 
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from the 2-day assessment to the 9-day assessment. The 
overall change from the pre-treatment to the 9-day assessment 
also shows a significant improvement •. The lack of initial 
significant improvement in the lorazepam can be explained 
as being due to the sedative effect of the drug. - By the 
9-day assessment the patients in the lorazepam group had 
adapted to the sedative effect (i.e. tolerance to the 
drug has occurred) and their PPT-P performance improves to 
a similar extent as that found in the other treatment groups. 
This is the first instance where the imp~irment in performance 
expected on the basis of volunteer. studies on lorazepam is 
found. If the patients had only been assessed at 
pre-treatment and at 9-days the impaired performance due 
to the sedative effect of lorazepam would not have been 
detected. Once again the clobazam group shows no indica-
tion of impaired performance and this is what would be 
expected on the basis of results of previous research on 
clobazam. 
The Purdue pegboard.test-both hands task mean scores show 
similar trends in all three treatment groups~ The initial 
improvement in performance is not significant but the 
improvement from the 2-day assessment to the 9-day assessment 
is significant. The overall improvement from pre-treatment 
to 9-days is significant. These improvements can be 
accounted for by a learning effect and anxiety reduction. 
The lack of impairment in the clobazam group is expected 
on the basis of findings on volunteers. On the other hand, 
-~· ~· 
one would have expected impairment in the lorazepam group 
on the basis of volunteer studies. 
The Purdue pegboard test-assembly task mean scores show 
very similar trends as that found for the preferred hand 
task. There are different trends in performance 
improvement over time in the three treatment groups. In 
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the placebo group there is a significant initial improvement 
from pre-treatment to 2-days followed by a slight insigni-
ficant improvement. The overall change from pre-treatment 
to the 9-day assessment is significant. The clobazam group 
shows a similar trend of initial significant improvement 
followed by a lack of significant improvement. In the 
lorazepam group there is a different trend. There is no 
' f. ' 
initial improvement from:pre-treatment to the 2-day assessment. 
The change from 2-days to 9-days is significant reaching 
a similar level of improvement to that found in the other 
two treatment groups. The change from pre-treatment to 
9-days is significant. The lack of initial improvement 
in the lorazepam group results in significant differences in the 
means of the lorazepam'group from the placebo and clobazam 
means at the 2-day assessment. 
The lack of initial improvement found in the lorazepam 
group can be attributed to the sedative effect of the drug 
which resulted in impaired performance. By the 9-day 
assessment the patients in the lorazepam group had adapted 
to the sedative effect and their PPT-A performance improves 
1.47 
to a similar extent as that found in the other treatment 
groups. On the basis of volunteer studies one would have 
expected impairment in the lorazepam group. If .the. 
patients had been assessed at pre-treatment and at 9-days 
the impairment in performance in the lorazepam group would 
not have been detected. The clobazam group shows no 
indication of impaired performance and this is what one 
would expect on the basis of findings on volunteers. 
The three treatment groups show similar trends in mean 
scores for the choice reaction time task. There is an 
initial significant improvement from pre-treatment to 2-days 
followed by a further significant improvement from 2-days 
to 9-days. This improvement can be attributed to a learning 
effect and anxiety reduction. Impairment would have been 
expected in the lorazepam group on the basis of volunteer 
studies. Once again the cl6bazam group showed no impairment 
and this is what one would have predicted on the basis of 
volunteer studies. 
In general the results show that there is far less impairment 
in the lorazepam group that what would be predicted on 
the basis of results from volunteer studies. The performance 
tests were selected on the basis that they are sensitive 
in detecting impaired performance in votunteers given 1,4 
benzodiazepines (including lorazepam). Thus impaired 
performance would be expected in most, if not all, of the 
performance tasks. Impaired performance is only found on 
.; \. 
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two of the pegboard tests. This shows very clearly that 
there is much less impairment in this group of patients than 
what would be expected on the basis of volunteer studies. 
As discussed in the introduction (Section 3.2), previous 
studies have also found a lesser frequency of impaired 
performance in patients. On the basis of the findings of 
this study and previous findings on patient groups it can 
be asserted that volunteer performance changes cannot serve as a 
definative basis for predicting what will happen in patients given 
1,4 benzodiazepine treatment. 
On the occasions where performance impairment was found 
in the lorazepam group the patients showed initial impair-
ment due to sedation followed by adaptation to the sedative 
effect and improvement in performance to the level found 
i· in the other treatment groups. These changes highlight 
the need for both a short-term and longer term assessment. 
Most volunteer studies include only a short-term assessment 
and many patient studies have only long-term (after one week) 
assessments. 
The clobazam group shows clear indications of less sedation 
than that found in the lorazepam group. There is no 
impairment on any of the performance tasks for patients 
in the clobazam group whereas the lorazepam group does show 
initial impairment on two of the pegboard tests. The 
clobazam group does not show significantly greater drowsiness 
ratings than the placebo group, in contrast the lorazepam 
. ~ - /• 
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group does show significantly greater drowsiness ratings. 
Since less impairment is found in the lorazepam group than 
that found in volunteei subjects, the degree of differen-
tiation from the clobazam group is much less than found 
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The intercom-elatlions between the anxiety measures and the visual 
analogue scale of motivation have already been discussed. 
The fairly strong trend for performance on the various 
performance variables to be related is what one would expect. 
A patient doing well on one of these pegboard tasks is very 
likely to do well on the other pegboard tasks and on other 
performance tasks which involve a speed component particu-
larly choice reaction time and to' a lesser extent the 
digit symbol substitutio~ test. There are, in fact, only 
three significant correlations between the Inglis paired-
associate learning test and the other performance measures 
i n d i cat i n g that the I n g 1 i s test .: sh a r: es 1 e. s s of the s k i 11 s 
than the other performance variables. 
The trend for performance to be inversely related to anxiety 
level is what woul.d be pred_icted by the general inverted-LI 
relationship between anxiety and performance. The fairly 
strong trend for drowsiness rati~g to be inversely related 
' ' .. ·, 
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to p~rformance in the clobazam group is very interesting. 
This implies th~t those patients with. high drowsiness ratings 
hav~ poor perform~nce and those patients with low drowsiness 
ratings have good performance. One would expect the 
·subjective ind(cation of sedation (drowsiness) to be related 
to the objective indication of sedation (impaired psycho-
motor performance). This relationship is surprisingly not 
shown in the lorazepam group where there are no significant 
correlations between dro~siness rating and the perform~nce 
variables. Some of the 'correlations are fairly 
substantial and approach significance. The relationship 
, I 
between subjectively experienced drowsiness and impaired 
psychomotor performance certainly needs to be investigated 
in future studies~ Quite possibly the lack of correlation 
between drowsiness level and impaired performance may be 
specific to this study. 
The few significant correlations between critical flicker 
fusion threshhold and the other variables are in the 
direction expected on the basis of previous experiments. 
Lower CFFT are associated with high anxiety levels (Goldstone, 
1955). Lower CFFT (lower arousal levels) are generally 
associated with poorer performance (Claridge, 1967). The 
two instances of significant positive correlation between 
drowsiness rating and the visual analogue scale of anxiety 
measure are not expected. The finding of only two significant 
correlations out of a possible 18 indicates a very minor 
relationship and is thus probably of minimal importance. 
. 't :; ' 
Before the impfications of the various findings are dis-
cussed, two important issues need to be considered. The 
first is the problem associated with doing a number of 
statistical tests on data from a single subject group. 
This is the problem of Type I errors. The second issue 
concerns the generalisability of ·the~findings. 
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7.3 TYPE I ERRORS 
' 
A type I error is the faulty conclusion that there are 
significant differences between measures when in fact the 
differences are actually due to chance. The probability. 
of a type I error for one particular statistical test is 
equal to alpha (o{) the level of significance. The values 
of alpha generally chosen in research are either 0,05 or the 
stricter level of 0,01. If one computes b independent tests 
of significance on the b dependent variables me~sured, then 
the probability of at least one type I error on all b tests 
is 1 - (1 - o< )b (Gilbert, 1977c). In this study there 
were 11 dependent variables (b =· 11) and the probability 
of c type I error for o< = 0,05 is p = 0,4013 and the 
probability of a type I error for o<. = 0,01 is p = 0,0956. 
If the level of significance chosen was 0,05 it can be seen 
that the probability of a type I error increases to a totally 
unacceptable level. However, if the significance level -
is 0,01 then the probability of· a type I error is still at 
an acceptable level of approximately 0,1. All except one 
of the ten significant two way anovas were significant at 
.,·' 
the 0,01 significance level and thus the degree of. 
significarce in nine instances was sufficient to decrease 
the chances of type I errors on any one statistical test 
to 0,1. 
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Another important factor specific to this study is the 
concern with trends in the changes in groups of dependent 
variables in both the two-way anovas and the correlations. 
There is relatively little emphasis laid on a finding of 
statistical significance in one particular dependent 
variable in the two-way anova analysis. This implies that 
since the probability of a type I error (when 11 tests are 
carried out and alpha set at 0,01) is approximately equal 
to 0,1 then-possibly one out of the ten significant findings 
could be due to chance. Since this study is interested 
in changes in groups of dependent variables (all the psycho-
motor performance measures) a single type I error is not 
going to affect the conclusions drawn from the findings. 
Similar arguments apply to the conclusions drawn from 
the correlations where one is interested in the trends in the 
relationship between groups of dependent variables. 
7.4 THE GENERALISABILITY OF THE FINDINGS 
When a random sample is drawn from a certain population 
group then the research findings derived from the sample 
are generalisable to the population group (Plutchik, 1974). 
There are thus two aspects which need to be discussed . 
.. . 
···.· .· 
Is the sample used in this study random? To what popu-
lation group are the results generalisable? 
The patients who participated in this research were those 
patients with anxiety problems who were prescribed a 
benzodiazepine tranquillizer by a doctor and who then 
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agreed to take part in the study. Most patients who were 
referred to the investigator agreed to participate. Only 
about ten patients did not agree to take part in the study 
because it would be inconvenient for them to return for 
another two appointments over the next nine days. 
The sample of patients can be considered to be a random 
sample of outpatients attending Retreat Day Hospital with 
anxiety problems who are viewed by a general practitioner 
as requiring benzodiazepine treatment. The sample is a 
selection of thege: patients over the particular time period 
,__ .... 
when the study was conducted relative to a longer period 
of time over which similar patients receive similar treat-
ment. This implies that the conclusions are certainly 
generalisable to patients with similar levels of anxiety 
who attend Retreat Day Hospital at other times. 
With a lesser degree of confidence the results can be 
generalised to outpatients with similar levels of anxiety 
and similar educational levels who attend other hospitals_. 
This generalisation would not be based on the strict 
criterion that the sample must be randomly drawn from a 
'•' .:, 
I , 
.\,." l; I I 
. I 
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population (that is not on fo~mal procedures of inference). 
Other non-statistical inferences to patient groups of 
different educational level can be made with less confi-
dence. Further empirical investigations ass~ssing the 
relationship between educational level and psychomotor 
performance on laboratory tests would be needed to adequately 
answer this question. Interestingly enough, the findings 
on psychomotor performance changes found in this study show 
similar trends to the findings found in other patient 
studies. Possibly the objective indications of sedation 
(impaired performance) are similar in most patients of a 
particular anxiety level regardless of other characteristics 
of the patients. 
The next parts of the discussion deal with some wider 
topics that relate to the findings of this study. 
7.5 REASONS FOR THE DIFFERENT INDICATIONS OF IMPAIRED 
PERFORMANCE IN PATIENT AND VOLUNTEER GROUPS 
The findings of this study indicate clearly that the fre-
quency of significant impairment on laboratory tests of 
psychomotor performance is less in patients than in 
volunteers given a 1,4 benzodiazepine (lorazepam). An 
overall considera~ion of all psychomotor performance 
studies on patient groups leads one to conclude that the 
findings in this study are consistent with previous findings 
'· ... ·~ 
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of a lesser frequency of impairment in patients relative 
to volunteers. 
A major reason for the lesser frequency of impairment.in 
patients is the initial higher level of anxiety experienced 
by the patients. The U-shaped relationship between 
anxiety and performance was discussed in the introduction 
(Section 2.3). Patients with relatively high initial 
levels are likely to have initially impaired performance. 
This has been shown in various studies (Lader and Marks, 
1971). When these patients are given a benzodiazepine their 
anxiety levels are reduced and their psychomotor performance 
thus improves. The benzodiazepines also have a sedative 
effect which will result in impaired performance~in the 
patients~ however, at the same time, because the patients 
are becoming less anxious, their performance is improving. 
The overall result is that•there is a lesser_ frequency 
of impaired performance in patients than in volunteers 
where only the sedative effect would be operating as the 
volunteers are non-anxious. 
..-
This explanation assumes an essentially similar effect of 
the benzodiazepine in anxious patients and non-anxious 
volunteers. However, there is some evidence that this 
may not be the case. DiMascio and Barrett (1965) and 
Barett and DiMascio (1966) found different effects in 
volunteers who had been divided into high and low anxious 
groups. The high anxious group of volunteers responded 
t56 
to the benzodiazepines in the.expected manner, their 
level of anxiety was significantly reduced .• The low 
anxious group in both,studies responded unexpectedly, 
their levels of anxiety increased significantly. This 
indicates that the benzodiazepines are possibly having 
different physiological effects in the low and h·tg~ anxious 
., 
groups. This could also result in djfferent degree~ 
of psychomotor performance impairment~ Possibly volun-
teers' performarice is disrupted by taking a benzodiazepine 
(their anxiety increases) and· this effect is not found in 
patients. Another poss(ble occurren~e is that the. 
benzodiazepines have different sedative effects in volunteers 
relative to patients. 
The discussion of Hollister (1981) ~bout benzodiazepine 
receptors is also relevant· to this issue. A remarkable 
discovery during the past two years has been the identifi-
cation of specific receptors in the brains of animals and 
man that bind be~zodiazepines. Hollister speculates 
that there is an endogenous ligand that binds to these re-
"' 
ceptors. In fact, several candidates for just such ligands-
have been proposed. The situation with the opiate drugs 
is analogous. Opiate recept9rs have been found and the 
endogenous opiate (endorphins) have been discovered. 
Hollister speculates further that those patients who have 
high levels of trait anxiety may iri fact be deficient in the 
end o g en o us 1 i g and for the be n z o d i a z e p i n e rec e.p tor . Th i s 
could mean that treatment with benzodiazepines would be far 
,' ~ 
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more specific than ordinarily believed. 
I would speculate further that if what Hollister hypothe-
sizes is correct the~ it does h~ve relevance to the 
different frequency of psychomotor performance impairment 
found in anxious patients relative to non-anxious volunteers. 
Non-anxious volunteers would not lack.this hypothesized 
endogenous ligand and when they were given a benzodiazepine 
there would bea resultant excess of benzodiazepine molecules 
which could lead to impaired performance either by seda-
tion or some other means. 
The two reasons proposed for the different frequency of 
impairment in volunteers and patients are not mutually 
exclusive and both may be relevant. 
7.6 THE PRACTICAL IMPLICATIONS OF THE FINDINGS 
A question that is important in ascertaining certain aspects 
of the practical implications of the findings is: How 
different is the sedative effect of clobazam to that of 
the 1,4 benzodiazepines (for this study lorazepam)? 
Certainly patients who receive a 1,4 benzodiazepine do 
experience both subjective sedation (drowsiness) and-objective 
sedation (impair~d performan~e). The frequency of impaired 
performance is less than in volunteers but it is still 
enough to be of practical significance. More research 
is needed but one can certainly even at this stage say 
' . 
i j ,·. 
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that patients who receive a 1,4 benzodiazepine should be 
cautioned about the possible detrimental effects of the 
treatment on performance. 
Further research. on the relationship of general findings 
of impaired psychomotor performance on laboratory tests to 
the specific practical situations such as car driving is 
needed. However, even at this stage it can be stressed 
that the cautioning about possible detrimental effects on 
psychomotor performance is particularly relevant to those 
patients who drive a car and to those patients whose occupa-
tions involve working with dangerous machinery. 
This study indicated some initial impairment for at least 
two days. At nine days there was no longer impaired 
performance. Further research is needed to ascertain at 
what point the patients adapt to their medication so that 
their performance is no longer impaired. 
To what extent should patients who receive clobazam be 
cautioned about possible imp~ired performa~ce? This study 
did not find any indications of impaired performance in the 
clobazam group. Subjective drowsiness ratings did not 
differ significantly from the placebo group. This would 
certainly seem to imply that clobazam is relatively free 
of both objective and subjective indications of sedation 
and that patients .who are given clobazam need not be cautioned 
about possible detrimental effects. However, a further 
t59 
careful consideration of the findings in this and other 
studies reveals that the situation may not be as clear cut 
as this. 
Lader (1979) discusses the physiological and biochemical 
studies on the benzodiazepines and concludes that 
"on theoretical grounds based on recent work, 
the anxiolytic and sedative properties of a 
benzodiazepine could be mediated through 
different pathways and perhaps different 
neuro transmitters. If so, then the ingenuity 
of medicinal chemists should make feasible the 
development of a drug which is anxiolytic 
without being sedative." (p.103 S). 
Is clobazam this drug? 
Although clobazam in this.study is free of significant 
impairment or drowsiness, there are indications that it is 
not totally free of sedation. ~ Some patients (eight) do 
report moderate drowsiness, especially at the day two 
assessment. When the individual psychomotor performance 
data for these patients are examined closely, it is clear 
that some of these patients do not show a similar extent 
of improved performance as found in the other clobazam 
patients. This is confirmed by the fairly strong trend 
for drowsiness ratings to be ·inversely related to performance 
(there are five out of twelve _significant correlations in 
the clobazam group at two days). It'seems that certain 
patients do experience both drowsiness and slightly 
impaired performance.· As noied in the introduction 
(Section 3.3) one study on volunteers also found that 
I 
• . •',i 
certain subjects (two of the ten subjects) were sensitive 
to clobazam showing impaired performance although no 
general statistically significant· indications of impaired 
performance were found when the results of all the volun-
teers who received clobazam were analysed (Hindmarch, 
Hanks and Hewett, 1977.). Previous research ·on both 
volunteers and clobazam.has only rarely· discerned statis-
tically significant indications of impaired performance, 
on most occasions there is no impairment or significant 
improvement is found. 
On the basis of this.study ~rid on previous research with 
clobazam on both volunteers and patients a number of 
conclusions concerning the sedative effect of clobazam can 
be stated . · C 1 ob a z am i s far 1 es s 1 i k e 1 y to res u 1 t in 
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impaired performance in patients than the 1,4 benzodiazepines. 
However, it seems that certain patients especially those 
who experience moderate dfowsiness. m11y also experience 
impaired performance. Further research in this area is 
needed and hence only tentative suggestions can be made 
as to the practical implications of these findings. A 
possible recommendation is that patients who take clobazam 
should still be cautioned about possible initial drowsiness 
with associated impaired performance although this is less 
likely to occur than in p~tients receiving a 1,4 benzodia-
zepine. 
. 1,.' 
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7.7 RECOMMENDATIONS FOR FUTURE RESEARCH 
A number of specific areas still need further investigation. 
The relationship between d~owsiness and impaired perform-
ance needs to be studied. Ass~ssments at other time periods 
need to be carried out to ascertain at what point full 
adaptation to sedative effects takes place. 
In addition to these specific ideas a general overall 
strategy can_be recommended for research into psychomotor 
performance changes induced by drugs. An adequate number 
of studies should be carried out on volunteers to ascertain 
the behavioural effects per se of a particular drug. In 
the past investigators have tended to mainly use volunteer 
subjects and this· study shows the necessity for doing at 
least as many studies as that done on volunteers on the actual 
patient group who will be receiving the drug. A standard 
battery of tests which have been shown to be sensitive 
to detecting impairment and which would assess all the 
important components of behaviour should be developed and 
used in these studies. In addition to these general 
assessments of psychomotor performance on laboratory tests 
specific studies on the performance of both volunteers 
and patients on practically relevant tasks such as car 
driving are also needed to be conducted for any particular 
drug which has properties that result· in impaired performance. 
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APPENDIX '2 '1 •• 
THREE ALTERNATIVE FORMS OF THE 
INGLIS PAIRED-ASSOCIATE LEARNING TEST 
Form A 
Stimulus Response 
cabbage pen 
knife chimney 
sponge trumpet 
-Form 
Stimulus 
tree 
cloud 
kettle 
' 
Form B 
Stimulus Response 
flower 
table 
bottle 
c 
Response 
fork 
drum 
book 
spark 
river 
comb 
(Devised by the 
investigator) 
t77 
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APPENDIX 3 
PATIENT CONSENT 
I, , hereby declare that I 
have given my consent for the procedure and/or treatment 
stipulated below. 
t78 
I have been fully informed by about the 
possible beneficial effects and also the possible detrimental 
effects which may occur to me as a result of the under-
mentioned procedure and/or treatment. 
I have also been fully informed by that 
the undermentioned procedure and/or treatment constitutes a 
, deviation from the normal procedure and/or treatment. 
The nature of the procedure and/or treatment is: 
The procedure and/or treatment shall be carried out by: 
My consent is granted·volwntarily and I realise that I may 
at any time withdraw my consent. 
SIGNED: 
Patient 
Person who informed Patient 
Person who will carry out procedure and/or treatment 
--~ - -··---·---· 
''·.' 
} ,• 
GASTRO-INTESTINAL SYMTOMS 
.. 
Difficulty in swallowing, wind, dyspepsia: pain before or 
after meals, burning sensations, fullness, waterbrach, 
nausea, vomiting, sinking feelings. Borborygmi, "working" 
in abdomen, looseness of bowels, loss of weight, constipa-
tion. 
GENITO-URINARY SYMPTOMS 
Frequency of micturition, urgency of micturition, 
amenorrhoea, menorrhagia, development of frigidity, 
ejaculatio praecox, loss of erection, impotence. 
DEPRESSED MOOD 
Loss of interest, lack of pleasure in hobbies, depression, 
early waking, diurnal swing. 
GENERAL SOMATIC (Muscular) 
Muscular pains and aches, muscular stiffness, muscular 
twitchings, clonic jerks, grinding of teeth, unsteady 
voice. 
GENERAL SOMATIC (Sensory) 
Tinnitus, blurring of v1s1on, hot and crild flushes, 
feelings of weakness, pricking sensations. 
CARDIOVASCULAR SYMPTOMS 
Tachycardia, palpitatio~s, pain in chest, throbbing of 
vessels, fainting feelings~ missing beat. 
RESPIRATORY SYMPTOMS 
Pressure or constriction in chest, choking feelings, 
sightings, dyspnoea. 
AUTONOMIC SYMPTOMS 
Dry mouth, flushing, pallor, t~ndency to sweat, giddiness, 
tension headache, raising of hair. 
j_ 8 0 
D 
D 
D 
D 
D 
D 
D 
D 
,.\ \ \ '. 
1. 81 
BEHAVIOUR AT INTERVIEW 
Tense, not relaxed. 
picking fingers. 
Fidgeting, and restlessness: Hands, D 
BEHAVIOUR PHYSIOLOGICAL 
Tremor of hands, furrowed brow, sfrained. face, facial 
pallor, swallowing, belching, sweating, eye-lid twitching. LI 
~ / 
. ~ t·, '!1 ··~ ) . ·:··-
/. 1,' .,1 
J.82 
.. • .. 
Name I Na am .................................. • ....... . 
Date /Datum 
Ek voel baie kalm. ·Ek voel baie angstig. 
I feel very calm . I feel very anxious. 
. '_, 
APPENDIX 6. 
Name I Na am 
Date I Datum ...........•............••.............. 
Ek het geen motivasie 
in my daaglikse bedry-
wighede. 
I have absolutely no 
motivation in my daily 
activities. 
Ek is deeglik gemoti-
veer in my daaglikse 
bedrywighede. 
I am extremely moti-
vated in my daily 
activities. 
1.83 
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1.84 
DETAILS OF PATIENTS 
Placebo Clobazam Lorazepam 
Patient Age School Standard Age School Standard Age School Standard Number Passed Passed Passed 
I 40 6 38 5 25 4 
2 25 4 45 I 55 5 
3 42 4 30 3 38 5 
4 36 8 35 3 31 5 
5 52 4 27 5 32 5 
6 40 5 19 7 22 5 
7 33 7 30 5 26 8 
8 43 5 41 4 42 5 
9 50 5 46 I 45 3 
10 20 4 28 5 21 6 
11 42 1 32 2 20 6 
12 24 5 20 9 27 3 
13 32 5 42 3 20 4 
14 63 5 18 5 37 5 
15 26 5 51 8 42 6 
16 34 3 44 4 36 6 
17 45 2 24 6 21 8 
18 18 7 . 37 3 23 5 
19 20 6 44 6 38 7 
20 25 6 39 6 57 2 
., 
21 51 6 21 3 
22 '38 3 40 3 
23 43 7 38 7 
24 21 4 
25 38 3 
26 27 2 
27 49 5 
·; . . v 
APPENDIX 8 
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RAW DATA4 
Hamilton Anxiety Scale 
Placebo Clobazam Lorazepam 
Patient Pre1 22 93 Pre 2 9 Pre 2 9 Number 
1 21 1 7 20 21 16 12 1 7 07' 5 
2 23 10 7. 31 15 8 30 1 1 7 
3 22 l 7 20 25 9 6 29 12 15 
4 23 12 1 7 28 16 10 29 15 16 
5 26 21 23 27 . 22 22 29 15 12 
6 19 10 10 23 19 15 25 14 11 
7 21 12 13 19 13 14 20 15 12 
8 1 7 14. 13 19 8 5 21 15 11 
I 9 21 15 13 24 19 1 3 26 15 11 
10 20 1 9 . 12 23 1 0 8 20 12 10 
1 1 29 15 13 28 21 19 1 7 12 10 
12 25 14 12 1 7 1 1 11 18 10 9 
13 13 1 0 10 12 6 5 23 19 12 
14 1 7 1 1 9 24 20 13 24 15 14 
.. 
15 21 16 14 26 16 9 25 16 12 
16 16 1 1 9 21 14 · 13 29 22 12 
1 7 24 22 1 9 14 7 6 23 1 7 1 1 
18 1 7 1 0 8 24 14 10 23 14 9 
19 16 12 1 0 21 19 10 20 1 5 9 
20 22 18 1 1 22 13 10 18 12 10 
21 15 1 1 8 27 21 18 
22 22 1 7 10 28 19 16 
23 23 18 1 1 29 17 10 
24 30 25 24 
25 27 1 9 1 9 
26 27 1 7 18 
27 21 12 1 7 
1. Pre-treatment assessment. 3. 9-day assessment. 
2. 2-day assessment. 4. Raw data are presented 
in the format that was 
used for the 2-way anovas. 
''· 
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Visual Analogue Scale for Anxiety 
Pl acebb Clobazam Lorazepam 
Patient Pre 2 9 Pre 2 .9 Pre 2 9 Number 
I 83 49 43 88 90 67 98 2 2 
2 71 21 2 91 57 41 93 48 13 
3 94 31 43 85 5 3 78 26 36 
4 88 14 2 77 38 21 74 24 21 
5 98 100 . 100 72 70 50 76 48 9 
6 2 2 4 23 2 2 82 31 24 
7 52 29 18 95 78 72 75 46 75 
8 74 80 71 73 25 2 75 22 9 
9 75 28 7 97 80 37 97 22 10 
1 o 71 83 47 81 4 3 90 63 13 
11 84 19 3-- 96 60 58 98 98 o 
12 95 28 21 . 73 48 38 98 3 10 
13 85 2 5 32. 20 12 86 56 21 . 
14 76 39 1 7 100 100 I 85 o 30 
15 92 54 51 99 45 1 96 34 24 
16 87 55 10 95 81 37 100 82 43 
1 7 80 87 66 59 3 4 87 37 33 
18 63 30 9 98 1 2 70 2 3 
19 60 33 14 79 91 4 62 25 3 
20 98 69 '8 99 83 2 85 70 6 
21 41 38 13 95 80 58 
22 95 97 20 99 62 45 
23 99 93 2 100 65 42 
I 24 100 96 97 
25 90 51 33 
26 94 57 41 
27 80 45 67 
" 
1.87 
Visual Analogue Scale for Motivation 
Placebo Clobazam Lorazepam 
Patient Pre 2 9 Pre Number 2 9 Pre 2 
9 
1 73 73 64 96 95 5 98 98 94 
2 
-· 
89 90 100 93 47 63 45 44 85 
... 
3 6 27 42 48 49 95 48 50 33 
4 63 94 63 79 
...... ...,...,. 
~;:; 24 75 37 23 
5 96 100 99 20 69 33 40 46 88 
6 96 97 97 93 100 99 85 50 39 
7 50 30 15 I 28 33 6 75 78 75 8 63 69 61 I 63 78 92 86 6 21 
9 90 96 96 I 68 .53 45 2 75 93 
10 81 89 96 i 72 98 99 1 3 82 72 I i 
1 1 8 70 97 ! 38 51 63 97 97 100 i 
12 2 8 17 I 44 55 73 3 86 91 I 
13 88 85 76 I 88 93 97 49 22 85 I 
. ' 
! 
14 66 88 94 ' : 0 0 100 5 2 54 
' 15 92 90 39 i 98 62 90 29 42 62 
16 84 91 85 30 83 65 64 57 51 
1 7 81 83 76 45 97 96 8 25 29 
18 27 31 60 4 99 97 98 97 97 
.; 
19 65 70 99 99 99 98 21 50 45 
20 2 34 82 97 97 93 28 55 80 
21 96 75 92 14 15 53 
22 4 2 2 6 8 21 
23 39 94 98 6 36 63 
24 70 95 97 
25 32 73 81 i 
26 15 55 55 i '' ! 
27 9 78 89 I 
I 
', ·'. . ' 
' ' :'" 
j_ 88 
Drowsiness Rating 
·-·. -~·· 
Placebo Clobazam Lorazepam 
---~-~--· 
Patient 2 9 2 9 2 9 Number 
1 0 0 2 2 l 0 
2 0 0 0 0 l {2) 
3 0 0 0 l 0 0 
4 0 0 0 1 0 2 
5 l 0 0 0 2 2 
6 0 0 0 0 2 0 
7 0 0 0 0 2 2 
8 0 0 0 0 l l 
9 0 0 l 0 0 0 
10 2 0 0 0 l l 
1 1 0 0 2 2 l 1 
12 2 2 0 0 2 l 
13 0 0 l l l l 
14 l 0 0 0 2 2 
15 0 0 2 0 l l 
16 0 0 2 . l 2 2 
1 7 0 0 . 0 0 l 0 
18 l 0 l 0 2 0 
19 0 0 2 2 l l 
20 l 0 2 0 1 0 
21 l 0 2 1 
22 l 0 2 2 
23 l 0 l 2 
24 2 2 
25 0 l 
26 1 l 
27 1 l 
/ 1.89 
Digit Symbol Substitution Test 
Placebo I Clobazam i Lorazepam I 
Patient ! Pre 2 9 Pre 2 9 ' Pre 2 9 Number I 
l 24,5 27 31, 5 29 33 31 20,5 24 24 
2 28 39 39 17 23,5 23 15,5 16,5 17,5 
3 16 18,5 23,5 17,5 30 31 19 23 28 
4 32,5 40 38 23 24,5 33 20,5 27,5 22,5 
5 18,5 18 14 33,5 39 29,5 30,5 26,5 33 
6 14 21 21,5 31 40 50 31 32,5 37,5 
7 38 49 53 35,5 47,5 49,5 33,5 37 43,5 
8 17 15 13 24 28 28 17 20 27 
9 35 40 45 6 9,5 5 13 11,5 10 
. l 0 38 45 46 22.5 33,5 39,5 25 33,5 40 
l l 18,5 26 33,5 8,5 10 16 33 34 27 ,5 
12 10 16 20,5 49 56 b1 15 21 25 
l 3 8,5 13 10 24,5 j 1 '5 44 22 24 28 
14 23,5 31, 5 37,5 30 34 35 16,5 24,5 27 
l 5 21'5 28 35,5 25,5 Q.\9 34,5 l(~p 20 31 ·~· 
16 30 35 35,5 10,5 19 24 17 27,5 27,'J 
1 7 8 11 10 37,5 54,5 57 38 40 54 
18 39 50,5 53,5 21 30 37,5 30 40 45,5 
19 29 38,5 36 38,5 46 47,5 30,5 29,5 39,5 
20 26,5 43,5 45,5 28 22,5 30,5 8 7,5 11,5 
21 22 27,5 27,5 9 16 21 
22 22,5 23,5 23 24 21 ,5 24 
I 23 29 j]4,5 37,5 18 20 22,5 I 
24 19,5 24 20,5 
25 .19 ,5 24 24 
26 23,5 26,5 32 
27 24 36,5 37,5 
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Inglis Paired-Associate Learning Test 
Placebo ~ Clobazam Lora zepam 
Patient I Pre 2 9 Pre 2 9 Pre 2 9 N~mber I \ I 
I 11 1 4 17 9 4 11 20 1 1 1 7 1 I 
2 14 11 12 30 33 14 1 0 21 7 
3 1 4 7 8 9 9 4 4 1 0 1 1 
I 
4 I 25 9 13 4 3 9 57 52 26 I 
5 I 20 9 11 35 19 Ft 5 8 5 6 24 8 1 8 12 4 4 12 4 8 
7 I 5 3 4 6 7 4 11 5 19 
' . 
8 1 0 6 1 5 12 12 9 18 4 4 
9 5 8 1 0 1 4 12 16 1 3 6 . 4 
I 
1 0 I 1 0 1 4 8 18 1 0 20 Ir, 6 4 5 
I 1 1 1 0 6 4 1 0 1 3 13 l 6 6 6 
12 25 1 4 1 3 7 . 9 1 0 1 0 6 5 
13 21 1 5 18 8 4 4 14 20 1 4 
.. ,,.._ 
14 8 7 11 21 6 ,'~f\ I-
'--,,::J 24 
11 . 15 
15 4 7 5 15 8 4 5 11 7 
16 8 7 10 8 8 1 0 9 5 4 
1 7 4 6 1 0 11 15 10 
I 
5 3 4 I 
1 
18 I 6 5 3 18 9 11 6 4 4 
1 9 I 6 ' 5 5 4 4 5 l 6 5 3 l 
20 I 5 5 3 8 9 :8 12 5 5 I 
21 I l 18 6 8 31 21 8 
22 I 14 9 7 19 4 5 ! I 
23 
I 5 6 4 
6 4 4 
24 1 0 8 .7 
I 
25 i 5 8 6 I I 
26 I 4 6 5 
I 
27 ; 7 .5 6 
' I 
·., 
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,, 
Purdue Pegboard Test ~ Pref erred Hand Task 
Placebo, Clobazam Lorazepam 
Patient Pre 2 9 Pre ·· 2 9 Pre 2 9 Number 
I 
1 l 17 . 1 8 17 14 1 6 1 3 1 5 16 1 8 
i 
2 ! 1 1 1 5 1 6 12 1 5 13 l 3 . l 3 l 5 ( 
3 i 12 l 2 12 15 18 1 7 14 l 3 1 3 
4 1 4 l 5 15 l 5 13 14 l l l 3 14 
5 14 l 6 1 5 17 l 2 15 14 l 4 15 
6 l l l 3 12 14 l 5 14 14 17 17 . 
7 ! hzj:) l l 3 13 18 l 3 14. l 5 l 6 l 6 j 
8 12 13 14 11 14 l 3 l 5 14 l 4 
9 
l 
\ 1 5 1 5 l 4 1 3 l 3, 11 1 3 12 14 
10 13 l 5 15 13 1 6 14 l 4 1 5 1 6 
1 1 12 16 l 7 l 0 1 1 13 l 3 l 3 1'4 
12 12 14 14 17 , 1 6 18 l 3 1 3 13 
13 l 4 l 5 l 6 1 4 1 6 l 7 14 1 4 1 5 
14 1 6 1 6 l 8 1 3 . 15 l 5 \ 18 16 16 
15 l 3 13 15 1 3 16 l 6 10 1 l 12 
16 15 1 7 15 12 1 3 l 3 15 l 5 1 5 
1 7 11 12 12 14 1 5 14 l 4 14 15 
18 114....,-\ l 6 18 11 l 4 14 15 13 l 5 
. '.,,-J 
1 9 11 1 3 l 3 16 l 5 14 11 l 3 14 
20 11 14 l 5 l 0 l 0 12 13 l 3 l 3 
21 12 l 3 l 3 i 9 10 l 3 i 
22 14 l 3 16 11 11 12 
23 1 2 1 3 l 3 1 5 15 17 
24 l 3 l 3 l l 
25 11 l 2 11 
26 11 5 l 6 1 6 
27 
., 
l15 16 01-5U 
I 
' 
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Purdue Pegboard Test Both Hands Task 
Placebo Clobazam Lorazepam 
Patient Pre 2 9 Pre Number 2 9 Pre 2 9 
1 
I 
i2 11 . 1 4 1 0 11 . 1 0 1 2 12 14 
2 1 0 1 2 1 1 11 1 2 12 9 9 10 
3 I 1 0 9 1 0 11 1 2 1 3 1 0 11 1 0 
4 I 1 0 1 2 1 2 1 0 1 0 1 0 1 0 1 0 1 0 
5 11 11 1 2 12 11 12 10 1 0 11 
6 9 1 0 9 12 12 12 1 1 1 2 12 
7 11 1 1 1 3 1 0 1 1 1 2 11 12 11 
8 l 1 0 1 0 12 1 0 8 1 0 9 10 9 
I 
9 I 11 11 1 1 8 9 8 9 1 1 10 
I 
10 1 0 1 0 11 9 g9 13 1 0 1 0 1 0 
1 1 9 1 1 1 0 8 7 9 9 .8 1 0 
12 9 1 1 12 12 ,. 13 1 1 8 8 9 
13 1 1 1 0 - 12 9 1 0 10 1 0 1 0 1 1 
14 1 2 1 3 1 1 8 10 1 0 , 11 1 3 1 1 
15 1 0 1 0 10 1 1 9 1 2 9 8 9 
16 12 1 0 12 .10 12 11 10 11 11 
1 7 I 8 9 9 10 l l 1 0 1 0 1 1 12 
18 I 12 1 1 1 3 9 9 11 9 l 0 10 
19 8 8 8 1 1 9 1 2 9 9 9 
20 9 1 0 1 1 7 7 8 l 0 9 9 
21 9 11 8 6 5 7 
22 12 1 1 12 8 7 7 
23 ·9 7 8 1 3 14 1 3 
24 9 1 0 9 
25 8 8 9 
26 l 1 12 12 
27 11 0 1 0 1 0 
195 
...... Purdue Pegboard Test Assembly Test 
Placebo Clobazam Lorazepam 
Patient Pre 2 9 Pre 2 9 Pre 2 9 Number 
1 37 44 52 36 48 44 36 52 58 
~ 
2 57 59 Ji? ... --- --. ,£ !~0 42 38 44 'l3 6) 
·) 
-----3 27 28 42 ~48 52 48 34 35 32 
4 50 54 50 51 52 48 36 36 46 
5 42 36 44 52 .52 ' 41 44 46 50 
6 36 42 42 52 52 56 48 56 54 
7 44 52 54 48 48 58 50 50 52 
8 48 50 38. 38 
_r'-";.. 
~J_J 48 42 44 46 
9 44 50 52 28 40 34 40 40 44 
10 54 58 54 32 50 52 50 50 60 
1 1 40 48 42 36 38 34 52 46 46 
12 44 44 46 56 54 56 42 34 42 
13 34 36 44 44 52 '48 38 38 44 
14 52 56 58 44 48 54 42 40 39 
15 46 54 44 ) 41 44 46 34 35 40 
16 46 46 S-o 42 44 46 44 46 58 
1 7 34 30 38 56 58 58 48 44 
,,, 
S"' 6 '~ 
18 56 54 49 32 46 48 42 44 48 
19 36 48 50 46 50 50 40 46 52 
20 44 52 52 44 32 36 312 34 38 ~~ 
21 40 54 44 20 21 20 
22 44 46 44 32 30 36 
23 36 42 42 48 46 54 
24 36 42 38 
25 28 36 2 6' 
26 48 46 52 
27 44 48 44 
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